

S1 Table. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist.



**PRISMA 2020 Checklist**

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	Pg 1
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pg 2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pg 5-8
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Pg 8
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pg 9-10, Supplementary Appendix S2
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pg 8-9, Supplementary Appendix S2
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Table 1, Supplementary Appendix S2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pg 10-11, Supplementary Appendix S2
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pg 10-15, Supplementary Appendix S2
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Pg 11-15, Supplementary Appendix S2
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Pg 11-15, Supplementary Appendix S2
Study risk of	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s)	Pg 11-15,

Section and Topic	Item #	Checklist item	Location where item is reported
bias assessment		used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary Appendix S2
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	NA
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Pg 11-15, Supplementary Appendix S2
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Pg 11-15, Supplementary Appendix S2
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Pg 11-15, Supplementary Appendix S2
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Pg 11-15, Supplementary Appendix S2
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	NA
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	NA
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Pg 11-15, Supplementary Appendix S2
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Pg 11-15, Supplementary Appendix S2
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Pg 16-17, Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Pg 16-17
Study characteristics	17	Cite each included study and present its characteristics.	Supplementary Table S3
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Pg 25-27, Figure 2-3

Section and Topic	Item #	Checklist item	Location where item is reported
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	NA
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Pg 17-27
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	NA
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	NA
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	NA
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Pg 25-27, Figure 2-3
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Pg 25-27, Figure 2-3
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Pg 27-31
	23b	Discuss any limitations of the evidence included in the review.	Pg 31-33
	23c	Discuss any limitations of the review processes used.	Pg 31-33
	23d	Discuss implications of the results for practice, policy, and future research.	Pg 33-34
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Pg 8
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Pg 8
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	With PLOS submission
Competing interests	26	Declare any competing interests of review authors.	With PLOS submission
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplementary Appendix S2

## Supplementary Appendix S2: Details on Review Methods

### Systematic review protocol

We developed a protocol per PRISMA guidance, and protocol drafts were reviewed by experts in the fields of menstruation and contraception who are members of the Global Contraceptive-Induced Menstrual Changes (CIMC) Task Force [1]. We registered our review protocol in PROSPERO (ID: CRD42023420358) [2].

### Search strategy

We conducted a multi-stage literature search in collaboration with the FHI 360 health sciences library to identify peer reviewed articles examining instruments to measure menstrual changes. First, we conducted preliminary searches in MEDLINE to refine our search strategy, including PubMed search terms recommended by the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) [3]. We then reviewed the 50 most relevant hits from the Embase, CINAHL, and PsycINFO databases to determine which should be included in our search strategy in addition to MEDLINE. Only Embase contained relevant articles within those 50 most relevant hits, so it was the only other database included in our final search. Table A shows the final search strategy for MEDLINE, which included largely Medical Subject Headings (MeSH) Major Topic terms and title or abstract search terms. The MEDLINE search strategy was adapted by an FHI 360 health sciences librarian for Embase (Table A). Final searches of MEDLINE and Embase were conducted, and the resulting records were uploaded into Covidence [4].

Table A. Search strategies

Database	Search strategy	Date searched
MEDLINE	("menstrual cycle"[MeSH Major Topic] OR "menstruation disturbances"[MeSH Major Topic] OR "Endometriosis"[MeSH Major Topic] OR "Uterine Diseases"[MeSH Major Topic] OR "menstrua*" [Title/Abstract] OR "menses"[Title/Abstract] OR "uterine bleeding"[Title/Abstract] OR "vaginal bleeding"[Title/Abstract] OR "amenorrhea"[Title/Abstract] OR "dysmenorrhea"[Title/Abstract] OR "menorrhagia"[Title/Abstract] OR "oligomenorrhea"[Title/Abstract] OR "metrorrhagia"[Title/Abstract] OR	Original: June 23, 2022  Updated: October 5, 2023

	<p>"hypermenorrhea"[Title/Abstract] OR                  "hypomenorrhea"[Title/Abstract] OR                  "polymenorrhea"[Title/Abstract])                  AND                  ("Surveys and Questionnaires"[MeSH Major Topic] OR                  "Pain Measurement"[MeSH Major Topic] OR "Patient                  Reported Outcome Measures"[MeSH Major Topic] OR                  "psychometrics"[MeSH Major Topic] OR "Sensitivity and                  Specificity"[MeSH Major Topic] OR "Validation                  Study"[Publication Type] OR "Validation Studies as                  Topic"[MeSH Major Topic] OR "measur*"[Title] OR                  "method*"[Title] OR "questionnaire*"[Title] OR                  "scale"[Title] OR "tool*"[Title] OR "patient reported                  outcome measure*"[Title/Abstract] OR                  "psychometr*"[Title/Abstract])                  AND                  ("2006/01/01"[Date - Publication] : "2023/10/05"[Date -                  Publication])</p>	
Embase	<p>('menstrual cycle'/exp/mj OR 'menstruation                  disorder'/exp/mj OR 'endometriosis'/exp/mj OR 'uterus                  disease'/exp/mj OR 'menstrua*':ab,ti OR 'menses':ab,ti                  OR 'uterine bleeding':ab,ti OR 'vaginal bleeding':ab,ti OR                  'amenorrhea':ab,ti OR 'dysmenorrhea':ab,ti OR                  'menorrhagia':ab,ti OR 'oligomenorrhea':ab,ti OR                  'metrorrhagia':ab,ti OR 'hypermenorrhea':ab,ti OR                  'hypomenorrhea':ab,ti OR 'polymenorrhea':ab,ti) AND                  ('measurement'/exp/mj OR 'questionnaire'/exp/mj OR                  'pain measurement'/exp/mj OR 'patient-reported                  outcome'/exp/mj OR 'psychometry'/exp/mj OR                  'sensitivity and specificity'/exp/mj OR 'validation                  study'/exp/mj OR 'measur*':ti OR 'method*':ti OR                  'questionnaire*':ti OR 'scale':ti OR 'tool':ti OR 'patient                  reported outcome measure*':ti,ab OR                  'psychometr*':ti,ab) AND [2006-2023]/py AND                  [embase]/lim NOT [medline]/lim</p>	<p>Original:                  June 28, 2022</p> <p>Updated:                  October 5, 2023</p>
NIH Common Data Element (CDE) Repository	<p>Searched menstruation-related pre-defined topic areas:</p> <ul style="list-style-type: none"> <li>• “menstruation scale”</li> <li>• “menstrual period regularity type”</li> <li>• “irregularity of menstrual cycle”</li> <li>• “menstrual cycle typical days PhenX”</li> <li>• “menstrual period last date”</li> <li>• “menstrual period occurrence indicator” (Oct 2023 search)</li> </ul>	<p>Original:                  October 11, 2022</p> <p>Updated:                  October 11, 2023</p>

COSMIN <sup>i</sup>	Keyword search for relevant instruments containing “menstru*” or “bleed*” in title	Original October 11, 2022  Updated October 11, 2023
COMET <sup>ii</sup>	Searched pre-defined Disease Names categories: <ul style="list-style-type: none"> <li>• “Abnormal uterine bleeding”</li> <li>• “Endometriosis”</li> <li>• “Endometriosis-related pain”</li> <li>• “Heavy menstrual bleeding”</li> <li>• “Uterine fibroids”</li> </ul>	Original October 11, 2022  Updated October 11, 2023
ePROVIDE	Keyword search for relevant instruments tagged “menstru*”, “dysmenorrhea”, or “menorrhagia”	Original October 11, 2022  Updated October 11, 2023

Next, we searched four instrument databases for any relevant instruments measuring menstrual changes: (a) the NIH Common Data Element (CDE) Repository [5], (b) the COSMIN database of systematic reviews of outcome measurement instruments [6], (c) the Core Outcome Measures in Effectiveness Trials (COMET) Database [7], and (c) ePROVIDE databases [8]. We detail search strategies for these instrument databases in Table A. Articles for any relevant instruments identified via these databases were uploaded into Covidence. We also planned to include instruments identified from searches of ClinicalTrials.gov and the Patient-Reported Outcomes Measurement Information System (PROMIS) database of measures, but multiple search strategies did not yield results we could screen and include.

Following screening and review of articles from the two literature databases (i.e., MEDLINE and Embase) and the four instrument databases (i.e., NIH CDE, COSMIN, COMET, and ePROVIDE), we completed two additional steps: (a) we extracted primary articles published since 1980 from all relevant review articles identified from the literature and instrument databases; and (b) we identified any original development articles for instruments developed before 2006. These primary articles and original development articles

---

<sup>i</sup> Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) database of systematic reviews of outcome measurement instruments

<sup>ii</sup> Core Outcome Measures in Effectiveness Trials

were then uploaded into Covidence for screening. Book chapters were excluded at this stage of screening.

Overall, our goal was to include all articles published on the (a) development, (b) validation, or (c) review of instruments since January 1, 2006. For instrument development or validation (a and b), we selected 2006 because the last major revision of standardized CIMC measurement in contraceptive clinical trials was published in 2007; therefore, that revision would encompass instruments developed or validated prior to 2006. For instruments reviewed (c), we selected 1980 as our date limit for extracting primary papers from identified reviews because the initial efforts to standardize CIMC measurement in contraceptive clinical trials, led by the World Health Organization (WHO), were in the 1980s; therefore, that WHO work would already encompass literature before 1980.

## Updated Search

After completing our systematic review, we conducted an updated search in October 2023 to ensure the results reported up-to-date findings. Original literature database searches (i.e., PubMed and Embase) covered January 1, 2006 through June 23, 2022, and updated searches covered June 23, 2022 through October 5, 2023. Original database searches (i.e., NIH CDE, COSMIN, COMET, and ePROVIDE) were conducted on October 11, 2022 and updates on October 11, 2023. For all identified articles in both searches, we completed the same search, screening, and review processes described in the main paper. The main paper reports on total results from all searches combined. Details on each search follow.

## Original search

Our original database searches yielded a total of 7,189 articles, of which 7,135 were from literature databases and 54 from instrument databases. Covidence removed 154 duplicates and we excluded 6,761 articles during title/abstract screening. During full text review, we excluded 93 articles for study design, article type, or population, 26 for not measuring menstrual changes, and 9 for no validation. We also identified one additional duplicate and found 23 relevant review articles. From these review articles we extracted 640 primary articles, of which 35 remained after title/abstract screening and full text review. During data extraction, we identified 6 instruments for which we did not have the original development papers, because either they were developed before 2006 (i.e., our search strategy date limit; n=5) or had not been captured via our search strategy (n=1). Across all sources, our searches yielded 7,835 articles. We removed 315 duplicates, excluded 7,171 articles during title and abstract screening, and excluded 190 articles during full text review. In total, we identified 159 relevant full text

articles of instruments developed, validated, or reviewed between January 1, 2006 and June 23, 2022.

We present the PRISMA diagram for the original search in Figure A.

### Updated search

Our original database searches yielded a total of 655 articles, of which 639 were from literature databases and 16 from instrument databases. Covidence removed 61 duplicates and we excluded 533 articles during title/abstract screening. During full text review, we excluded 22 articles for study design, article type, or population, 15 for not measuring menstrual changes, and 9 for no validation. We identified no relevant review articles, and no instruments for which we did not have the original development papers. In total, we identified 15 additional relevant full text articles of instruments developed, validated, or reviewed between June 23, 2022 and October 5, 2023. We present the PRISMA diagram for the updated search in Figure B.

The updated search yielded 15 additional articles on 11 full instruments (including 2 articles on one instrument, the EHP-30) and 3 broader instruments that included sub-scales (n=1) or a small number of items (n=2, both of which were not identified in the original search). Of the 11 new full instruments, 4 had not been identified in the original search (i.e., Pain Drawing, the World Health Organization Disability Assessment Schedule 2.0, the Bleeding and Pelvic Discomfort Scale, and the PERIOD-QOL).



Figure A: Original search PRISMA diagram





Figure B: Updated search PRISMA diagram



## Inclusion/exclusion criteria

We included all peer-reviewed articles—including those with prospective, retrospective, or cross-sectional study designs, and review papers—that met our inclusion and did not meet our exclusion criteria. We detail these criteria in Table B, but briefly, we included articles that: (a) reported on the development or validation of instruments to measure menstrual changes, (b) used mixed methods or quantitative approaches, and (c) were published between January 1, 2006 and October 5, 2023. We did not impose any restrictions on article language, country, or geographic region. Articles using only qualitative methods and conference abstracts, editorials, and commentaries were excluded because they would not contain the information necessary to evaluate instrument quality and utility for clinical trials, per our second review question.

**Table B: Inclusion and exclusion criteria**

Inclusion criteria	<ol style="list-style-type: none"> <li>1. Articles primarily focused on developing, validating, and/or evaluating instruments measuring menstrual changes or perceptions of menstrual changes, with information reported to assess instrument and/or study quality</li> <li>2. Articles published between January 1, 2006 and October 5, 2023</li> <li>3. Articles published in any language</li> <li>4. Articles from any geographic region</li> </ol>
Exclusion criteria	<ol style="list-style-type: none"> <li>1. Articles with only qualitative data</li> <li>2. Articles that were conference abstracts, editorials, and commentaries</li> <li>3. Articles whose primary purpose was not validating instruments measuring menstrual change, such as studies focusing on biomarkers or biological pathways of menstrual changes, cancer screening instruments, or studies of social-behavioral correlates of menstrual changes</li> <li>4. Articles reporting only on data from people in menopause</li> </ol>

Our definition of menstrual changes was adapted and broadened from the Global CIMC Task Force definition of changes to the menstrual cycle caused by contraception [1]. For the purposes of this review, the term, **menstrual changes**, includes four aspects (a) bleeding duration, volume, frequency, and/or regularity/predictability; (b) blood consistency, color, and/or smell; (c) pain or cramping; and (d) perceptions of bleeding, blood, or pain. We define perceptions as the perspectives on, attitudes about, experiences with, and acceptability of menstrual changes at the individual-level, interpersonal-level, community-level, and wider levels, including social norms. Examples of these four aspects of menstrual changes are: (a) an increase in how long bleeding lasts (bleeding duration), (b) a reduction of clotting (blood consistency), (c) a decrease in dysmenorrhea (pain), and (d) an impact on quality of life or attitudes (perceptions of changes).

We use the single term ‘**instrument**’ to capture any measure, method, or approach to assess menstrual changes, including healthcare provider-reported, menstruator-reported, researcher-based, biomarker-based, or assay-based methods, and including those that may be deemed “objective” or “subjective” and both directly observable and personal perceptions of menstrual changes (adapted from [9]). Our definition of **development** or **validation** of instruments was intentionally broad, including any manner of validation or evaluation (e.g., reporting any evidence on validity, reliability, responsiveness, interpretability, and other attributes of measure quality or utility) and any development or validation informed by input from research participants who menstruate.

### Developing data extraction forms and instrument evaluation

One author (SC) drafted the initial template data extraction form in Excel after input from the rest of the authors, and all authors reviewed and gave feedback on the draft data extraction form. The final data extraction form collected information in five areas: article information, study design and sample information, details on the instrument, measure quality attributes, and clinical trial utility attributes.

Table C has details on the fields of the data extraction form for each of the five areas.

Table C: Fields of data extraction form.

Information area	Information fields
1. Article information	<ul style="list-style-type: none"> <li>• Author initials</li> <li>• Date extraction completed</li> <li>• Covidence ID number</li> <li>• First author</li> <li>• Publication year</li> <li>• Title</li> </ul>
2. Study design and sample information	<ul style="list-style-type: none"> <li>• Region</li> <li>• Country</li> <li>• Language</li> <li>• Sample size (analysis sample)</li> <li>• Sample characteristics (age range, any condition or diagnosis, source [e.g., clinic-based, household-based, school-based, other])</li> <li>• Study design</li> <li>• Number of cycles per participant</li> <li>• Number of cycles total</li> <li>• Date of data collection</li> <li>• Electronic data collection</li> <li>• Validation methodology</li> </ul>
3. Instrument details	<ul style="list-style-type: none"> <li>• Measure evaluated or validated as the primary measure</li> <li>• Type of tool (full questionnaire, subscale, 1-2 questions, laboratory assay)</li> <li>• Who fills out tool (patient at home, patient at clinic, clinician, researcher)</li> </ul>

	<ul style="list-style-type: none"> <li>• Measure or measures used as comparison group for primary measure under consideration</li> <li>• All menstrual changes the instrument can measure</li> <li>• Menstrual changes measurement validated in the study</li> </ul>
4. Measure quality criteria	<ul style="list-style-type: none"> <li>• Conceptual and measurement model</li> <li>• Reliability</li> <li>• Content validity</li> <li>• Construct validity</li> <li>• Responsiveness/dynamism</li> <li>• Sensitive nature of questions</li> </ul>
5. Clinical trial utility criteria	<ul style="list-style-type: none"> <li>• Interpretability of results</li> <li>• Transferability</li> <li>• Participant burden</li> <li>• Investigator burden</li> </ul>

For assessing measure quality and clinical trial utility, one author (SC) reviewed existing evaluation criteria and tools from the literature and guidance documents on selecting instruments for clinical trials (e.g., see Crossnohere *et al.*, 2021 [10] for a recent overview) with input from the rest of the authors. After considering several alternatives (e.g., COSMIN Risk of Bias checklist [11], Francis *et al.*'s checklist to operationalize measurement characteristics of PRO measures [12], and the International Professional Society for Health Economics and Outcomes Research (ISPOR) PRO Good Research Practices Task Force guidance [13,14]), we determined these approaches did not meet our needs due to being too burdensome, too binary, or not specific to evaluation, respectively. We decided to follow the Patient-Reported Outcomes Tools: Engaging Users and Stakeholders (PROTEUS) Consortium recommendations to use International Society for Quality of Life Research (ISOQOL) standards for PRO measures [15,16]. We made two adjustments to the ISOQOL standards: (a) we added an attribute on sensitivity of questions given the topic of menstruation has a noted amount of stigma surrounding it [17]; and (b) we separated out participant burden from investigator burden given these two can differ greatly for instruments measuring menstrual changes. We categorized six attributes as related primarily to the quality of the instrument (i.e., **measure quality**: conceptual/measurement model, reliability, content validity, construct validity, responsiveness, and sensitive nature of questions) and four attributes as related primarily to the utility of the instrument in clinical trials (i.e., **clinical trial utility**: interpretability of results, the transferability of the instrument, participant burden, and investigator burden).

We scored each attribute of measure quality and clinical trial utility on a scale from 0 to 3, where 0 indicated there were **no data** reported on the attribute, 1 indicated **poor** measure quality/clinical trial

utility of the attribute, 2 indicated **fair** measure quality/clinical trial utility of the attribute, and 3 indicated **good** measure quality/clinical trial utility of the attribute. Criteria for scoring of an attribute was defined in line with ISOQOL standards [16] and reviewed by measurement and clinical experts at FHI 360 and within the Global CIMC Task Force. We show the measure quality and clinical trial utility attributes and scoring criteria in Table D.

Table D: Measure quality and clinical trial utility scoring criteria\*

Attribute	Poor quality (1)	Fair quality (2)	Good quality (3)
<b>Measure quality</b>			
<b>Conceptual and Measurement Model</b> Definition: The conceptual model provides a description and framework for targeted construct(s) in the measure. The measurement model maps individual measure items to the construct(s). <i>Score 0 if not assessed in article.</i>	Minimal discussion of conceptual model or measurement model that maps measure items to the construct(s). Or minimal discussion of intended population or context for measure use.	Some discussion of conceptual and/or measurement model that maps measure items to the construct(s). Or some discussion of intended population and/or context for measure use.	Clearly defines and describes concept(s) included in model and intended population(s) and context for measure use. Or clearly describes how concept(s) are organized into measurement model, including evidence for dimensionality of the measure, how items relate to each measured concept, and the relationship among concepts.
<b>Reliability</b> Definition: The degree to which a measure is free from measurement error. <i>Score 0 if not assessed in article.</i>	There is minimal evidence for measure reliability (e.g., internal consistency reliability, test-retest reliability, or item response theory)	Unclear or unjustified methodology used for assessing reliability. Or, if used, reliability Cronbach $\alpha < 0.70$ for group-level comparisons without justification.	Methodology for collecting data is justified (e.g., a multi-item measure is assessed for internal consistency reliability and a single-item measure is assessed by test-retest reliability or item response theory). Or, if used, reliability Cronbach $\alpha \geq 0.70$ for group-level comparisons. If lower, there is clear and appropriate justification.
<b>Content Validity</b> Definition: The extent to which the measure includes the most relevant and important aspects	Minimal evidence participants or experts consider the measure relevant and comprehensive.	Some evidence participants and experts consider the measure relevant and/or comprehensive	Clear evidence participants and experts consider the measure relevant and comprehensive for the

Attribute	Poor quality (1)	Fair quality (2)	Good quality (3)
<p>of a concept in the context of a given measurement application. <i>Score 0 if not assessed in article.</i></p>	<p>Or minimal documentation of methodology for evaluating content validity.</p>	<p>for the concept, population, and/or intended application. Or some evidence of methodology used to evaluate content validity. Or the paper mentions past validation research (i.e., focus groups, pilot studies, formative research) but does not provide detail on these studies.</p>	<p>concept, population, and intended application. And clear evidence of methodology used to evaluate content validity, including for assessing the relevance of measured concept(s), comparing validation study sample to the wider target population, and justification for recall period.</p>
<p><b>Construct Validity</b> Definition: The degree to which scores on the measure relate to other measures (e.g., patient-reported or clinical indicators) in a manner that is consistent with theoretically derived a priori hypotheses concerning the concepts being measured. <i>Score 0 if not assessed in article.</i></p>	<p>Minimal evidence supporting pre-determined hypotheses related to construct validity.</p>	<p>Some evidence supporting pre-determined hypotheses related to construct validity.</p>	<p>Clear evidence supporting pre-defined hypotheses on the expected associations among other measures similar or dissimilar to the studied measure.</p>
<p><b>Responsiveness/dynamism</b> Definition: The extent to which a measure can detect changes in the construct being measured over time. <i>Score 0 if not assessed in article.</i></p>	<p>Minimal evidence the measure can detect changes consistent with pre-defined hypotheses related to responsiveness. Or minimal evidence the measure can detect changes within or among participant groups.</p>	<p>Some evidence the measure can detect changes consistent with pre-defined hypotheses related to responsiveness. Or some evidence the measure can detect changes within or among participant groups.</p>	<p>Clear evidence the measure can detect changes consistent with pre-defined hypotheses in the target population for the intended application. And clear evidence the measure can detect changes within or among participant groups.</p>
<p><b>Sensitive nature of items</b> Definition: How measure addresses questions of sensitive topics, including those that are seen as intrusive, posing a threat of disclosure, or eliciting socially desirable answers. <i>Score 0 if not assessed in article.</i></p>	<p>Minimal evidence about measure or item sensitivity Or evidence of sensitivity that may result in biased responses</p>	<p>Some evidence or discussion about measure or item sensitivity Or some evidence of reduced sensitivity that would not result in biased responses</p>	<p>Clear evidence about measure or item sensitivity And clear evidence of reduced sensitivity that would not result in biased responses</p>
<b>Clinical trial utility</b>			
<p><b>Interpretability of results</b> Definition: The degree to which one can easily understand a</p>	<p>Minimal evidence for interpreting results.</p>	<p>Some evidence for interpreting results.</p>	<p>Clear evidence of interpreting results, including</p>

Attribute	Poor quality (1)	Fair quality (2)	Good quality (3)
<p>measure's results (e.g., scores, levels). <i>Score 0 if not provided in article.</i></p>	<p>Or minimal evidence results are understood by relevant stakeholders. There is no clinically relevant minimum change or no assessment of clinical relevance.</p>	<p>Or some evidence results are understood by relevant stakeholders, including patients, clinicians, and/or researchers. There is an agreement on clinically relevant minimum change and/or assessment of clinical relevance.</p>	<p>differentiating between differing outcomes (e.g., high and low scores), and/or what constitutes a large or small change in the measured concept. And evidence results are clearly understood by multiple relevant stakeholders, including patients, clinicians, and researchers. There is an accepted clinically relevant minimum change.</p>
<p><b>Transferability</b> Definition: The degree to which the measure can be transferred between linguistic and sociocultural groups. <i>Score 0 if not provided in article.</i></p>	<p>Minimal evidence measurement properties are maintained across linguistic and/or cultural groups.</p>	<p>Some evidence measurement properties are maintained across linguistic and/or cultural groups.</p>	<p>Clear evidence measurement properties are maintained across linguistic or cultural groups, including qualitative testing of the translated measure.</p>
<p><b>Participant Burden</b> Definition: The time, effort, resource (e.g., use or ownership of smart phone, internet access refrigeration), and other demands placed on those to whom the measure is administered. <i>Score 0 if not provided in article.</i></p>	<p>Measure requires more than 20 minutes† to complete (&gt;40 questions), requires data collection daily or multiple times a day, and/or multiple clinic visits or daily data collection outside the home. Or there is no information on expected participant time burden. Or the measure requires resources not available to most participants. Or there is minimal information on literacy demand of measure items or appropriateness for proposed context.</p>	<p>Measure requires between 15-20 minutes† to complete (20-40 questions), and/or one or two clinic visits, including those that are a burden to participant. Or there is limited information on expected participant time burden, including limited or no input from participant review panels. Or the measure may require some resources can be a barrier to some participants. Or literacy demand of measure items is above a 6th grade level (i.e., &gt;12-year-old) and not appropriately justified for proposed context.</p>	<p>Measure requires less than 15 minutes† to complete (&lt;20 questions), no daily data collection, and no more than one clinic visit. Or there is an accurate description of the expected participant time burden with approval from participant review panels. Or there are no resource barriers to participants. And literacy demand of measure items is at a 6th grade level or lower (i.e., ≤12-year-old), or literacy level is appropriately justified for proposed context.</p>

Attribute	Poor quality (1)	Fair quality (2)	Good quality (3)
<p><b>Investigator Burden</b>                      Definition: The time, effort, resource, and other demands placed on those who administer the measure.                      Score 0 if not provided in article.</p>	<p>There is a high burden on the data collection team due to: (a) data collector training being time or cost prohibitive with a lack of available training materials; (b) a high data monitoring burden to maintain quality data; (c) measure scoring being complex; or (d) measure inflexible or resource intensiveness (e.g., can only be interviewer-administered or requires tablet or computer).                      Or there is minimal information on investigator burden.</p>	<p>There is a modest burden on the data collection team due to: (a) the time and cost of data collector training or lack of training materials; (b) data monitoring burden; (c) modest measure scoring complexity; or (d) the measure being either flexible or not resource intensive.                      Or there is limited information on investigator burden.</p>	<p>There is a low burden on a data collection team due to (a) minimal requirement for data collector training and availability of training materials; (b) low data monitoring burden, (c) measure scoring being simple, or (d) the measure being flexible and not resource intensive (e.g., either measure is completed by the participant or is easily explained and completed).                      Or there is an accurate description of the expected investigator burden.</p>

\* Attributes and definitions from Reeve *et al.* 2013 [16] per PROTEUS-Trials Consortium guidance [15], with modified as specified in the text.

† Crossnohere *et al.*, 2021 [10].

## Process for title/abstract screening, full text review, and data extraction

The authors met with the FHI 360 health sciences library team for a month to finalize the search strategy and then began weekly author meetings to discuss progress, questions, and discordance, and to document decisions and progress in a shared Word document. We began title/abstract screening with an ‘inter-reviewer reliability’ meeting where all authors completed title/abstract screening on the same 50 articles to establish and confirm group standards. Then, two authors independently screened each remaining title/abstract and two authors independently reviewed each relevant full text in Covidence. We resolved any discordance during weekly meetings via consensus conversations. We used the text translation feature of Google Translate to review abstracts not in English during screening, and we used the document translation feature of Google Translate and/or consulted a fluent colleague to review full text articles that were not in English. We used the notes and tag features in Covidence to document questions between meetings, consensus decisions during meetings, and any translation from Google Translate. We used Excel worksheets for data extraction. For instruments reported in more than one article, we concurrently extracted all articles on each instrument. We conducted data extraction with a fluent colleague for full text articles not in English. During title/abstract screening, full text review, and



data extraction, when the authors had finished with approximately 5% of the articles, the following weekly author meeting included a specific discussion on the need for any clarifications or minor modifications to our inclusion/exclusion criteria for screenings/review or data extraction forms. After these '5% discussions', we made only minor clarifications to the inclusion/exclusion criteria and added or revised only a few fields in the data extraction forms.

## Data analysis

Two authors (EH and SC) developed the initial analysis plan with input from the rest of the authors, and one author (EH) compiled all extracted data and conducted initial analyses with data checks by the rest of the authors. After data compilation, all authors conducted parts of the analysis. All analysis was conducted in Excel and included counts and frequencies, as well as specific analyses to assess (a) measure quality and (b) clinical trial utility. For these two outcomes, two authors (EH and SC) developed a scoring system with input from other authors in order to assign each instrument a measure quality score, a clinical trial utility score, and a total evidence score. For **measure quality scores** and **clinical trial utility scores**, we used an average of the highest score for each attribute of measure quality or clinical trial utility across all articles on an instrument. Because instruments could have more than one article providing data on measure quality and/or clinical trial utility and not every article evaluated all attributes, we did not include scores of zero (i.e., no data reported) in the measure quality and clinical trial utility scores. To reflect these differences in the number of articles and attributes reported in the article(s), we also calculated a total **evidence score**, which was the total of all scores—including zeros—across all attributes of measure quality and clinical trial utility. The total evidence scores, therefore, 'penalize' instruments for a lower level of evidence due to fewer articles or less attribute data and vice versa.

These three scores—measure quality (ranging from 1-3), clinical trial utility (ranging from 1-3), and total evidence (ranging 0+)—reflect different dimensions of an instrument. For example, two instruments might both have a score of 2.5 for measure quality, but one instrument might have an evidence score of 10 and the other, 100, indicating the latter has considerably more evidence and likely more certainty in the measure quality score. Alternately, two instruments may have similar measure quality and evidence scores, but one may have a clinical trial utility score of 1 and the other a score of 3, indicating the latter is likely better suited for use in clinical trials despite the similar levels of measure quality and evidence.

## References

1. Hoppes E, Nwachukwu C, Hennegan J, Blithe DL, Cordova-Gomez A, Critchley H, et al. Global research and learning agenda for building evidence on contraceptive-induced menstrual changes for research, product development, policies, and programs. *Gates Open Res.* 2022;6: 49. doi:10.12688/gatesopenres.13609.1
2. Mackenzie A, Chung S, Hoppes E, Cartwright A, Mickler A. Measurement of changes to the menstrual cycle: A systematic review protocol. PROSPERO . 2023;CRD42023420358. Available: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42023420358](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023420358)
3. Terwee CB, Jansma EP, Riphagen II, de Vet HCW. Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. *Qual Life Res.* 2009;18: 1115–23. doi:10.1007/s11136-009-9528-5
4. Veritas Health Innovation. Covidence Systematic Review Software. [cited 24 Jul 2023]. Available: <https://www.covidence.org>
5. US National Library of Medicine, US National Institutes of Health. NIH Common Data Elements Repository. [cited 11 Oct 2023]. Available: <https://cde.nlm.nih.gov>
6. University Library Vrije Universiteit Amsterdam. COSMIN database of systematic reviews of outcome measurement instruments. [cited 11 Oct 2023]. Available: <https://database.cosmin.nl>
7. Core Outcome Measures in Effectiveness Trials (COMET) Initiative. COMET database. [cited 11 Oct 2023]. Available: <https://www.comet-initiative.org/Studies>
8. Mapi Research Trust. ePROVIDE. [cited 11 Oct 2023]. Available: <https://eprovide.mapi-trust.org>
9. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. *Measurement in Medicine*. Cambridge University Press; 2011. doi:10.1017/CBO9780511996214
10. Crossnohere NL, Brundage M, Calvert MJ, King M, Reeve BB, Thorner E, et al. International guidance on the selection of patient-reported outcome measures in clinical trials: a review. *Qual Life Res.* 2021;30: 21–40. doi:10.1007/s11136-020-02625-z
11. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res.* 2010;19: 539–49. doi:10.1007/s11136-010-9606-8
12. Francis DO, McPheeters ML, Noud M, Penson DF, Feurer ID. Checklist to operationalize measurement characteristics of patient-reported outcome measures. *Syst Rev.* 2016;5: 129. doi:10.1186/s13643-016-0307-4
13. Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. *Value Health.* 2009;12: 1075–83. doi:10.1111/j.1524-4733.2009.00603.x
14. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO)

instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. *Value Health*. 2011;14: 978–88. doi:10.1016/j.jval.2011.06.013

15. Snyder C, Crossnohere N, King M, Reeve BB, Bottomley A, Calvert M, et al. The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials. *Clin Trials*. 2022;19: 277–284. doi:10.1177/17407745221077691
16. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res*. 2013;22: 1889–905. doi:10.1007/s11136-012-0344-y
17. Johnston-Robledo I, Chrisler JC. The Menstrual Mark: Menstruation as Social Stigma. In: Bobel C, Winkler I, Fahs B, Hasson K, Kissling E, Roberts T, editors. *The Palgrave Handbook of Critical Menstruation Studies*. Singapore: Springer Singapore; 2020. pp. 181–199. doi:10.1007/978-981-15-0614-7\_17

S3 Table. All articles included after title/abstract screening and full text review.

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
<b>Studies validating/evaluating full instruments (n=133)</b>						
Aberdeen Menorrhagia Severity Scale	Ruta	1995	Europe	United Kingdom	Cross-Sectional	[1]
Aberdeen Menorrhagia Severity Scale	Abu-Rafea	2012	Middle East	Saudi Arabia	Cross-Sectional	[2]
Adolescent Dysmenorrhic Self-Care Scale	Ching-Hsing	2004	Asia	Taiwan	Cross-Sectional	[3]
Adolescent Dysmenorrhic Self-Care Scale	Wong	2013	Asia	Hong Kong	Cross-Sectional	[4]
Alkaline Hematin Assay	van Eijkeren	1986	Europe	Netherlands	Prospective Cohort	[5]
Average cycle length - self report	Small	2007	North America	United States	Prospective Cohort	[6]
Bleeding and Pelvic Discomfort Scale	Hudgens	2022	Multiple	Multiple	Randomized Controlled Trial	[7]
Daily diary, menopause classification	Paramsothy	2013	North America	United States	Prospective Cohort	[8]
Daily diary, menstrual cycle length	Johannes	2000	North America	United States	Prospective Cohort	[9]
Dysmenorrhea Daily Diary	Nguyen	2015	North America	United States	Cross-Sectional	[10]
Dysmenorrhea Daily Diary	Nguyen	2017	Multiple	Multiple	Cross-Sectional	[11]
Dysmenorrhea Symptom Interference Scale	Chen	2021	North America	United States	Mixed methods	[12]
electronic Personal Assessment Questionnaire - Menstrual, Pain, and Hormonal	Gray	2019	Europe	United Kingdom	Cross-Sectional	[13]
Endometriosis Daily Diary	Guan	2022	North America	United States	Prospective Cohort	[14]
Endometriosis Daily Pain Impact Diary	Wyrwich	2018	North America	United States	Prospective Cohort	[15]
Endometriosis Health Profile-30	Jones	2001	Europe	United Kingdom	Cross-Sectional	[16]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Endometriosis Health Profile-30	Mengarda	2008	South America	Brazil	Cross-Sectional	[17]
Endometriosis Health Profile-30	Grundstrom	2020	Europe	Sweden	Cross-Sectional	[18]
Endometriosis Health Profile-30	Grundstrom	2020	Europe	Sweden	Cross-Sectional	[19]
Endometriosis Health Profile-30	Jones	2004	Europe	United Kingdom	Prospective Cohort	[20]
Endometriosis Health Profile-30	Jenkinson	2008	North America	United States	Cross-Sectional	[21]
Endometriosis Health Profile-30	Hansen	2022	Europe	Denmark	Cross-Sectional	[22]
Endometriosis Health Profile-30	Khong	2010	Oceania	Australia	Cross-Sectional	[23]
Endometriosis Health Profile-30	Verket	2018	Europe	Norway	Cross-Sectional	[24]
Endometriosis Health Profile-30	Jones	2006	Europe	United Kingdom	Cross-Sectional	[25]
Endometriosis Health Profile-30	van de Burgt	2011	Europe	Netherlands	Case Control	[26]
Endometriosis Health Profile-30	Van de Burgt	2013	Europe	Netherlands	Prospective Cohort	[27]
Endometriosis Health Profile-30	Wickstrom	2017	Europe	Sweden	Prospective Cohort	[28]
Endometriosis Health Profile-30	Nojomi	2011	Middle East	Iran	Cross-Sectional	[29]
Endometriosis Health Profile-30	Mansor	2023	Asia	Malaysia	Cross-Sectional	[30]
Endometriosis Health Profile-30	Maiorana	2012	Europe	Italy	Cross-Sectional	[31]
Endometriosis Health Profile-30	Marí-Alexandre	2022	Europe	Spain	Cross-Sectional	[32]
Endometriosis Health Profile-30	Nogueira-Silva	2015	Europe	Portugal	Cross-Sectional	[33]
Endometriosis Health Profile-30	Chauvet	2017	Europe	France	Cross-Sectional	[34]
Endometriosis Health Profile-30	Jia	2013	Asia	China	Cross-Sectional	[35]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Endometriosis Health Profile-5	Jones	2004	Europe	United Kingdom	Cross-Sectional	[36]
Endometriosis Health Profile-5	Fauconnier	2017	Europe	France	Case Control	[37]
Endometriosis Health Profile-5	Aubry	2017	Europe	France	Prospective Cohort	[38]
Endometriosis Health Profile-5	Mikuš	2023	Europe	Croatia	Prospective Cohort	[39]
Endometriosis Health Profile-5	Selcuk	2015	Europe	Turkey	Case Control	[40]
Endometriosis Impact Questionnaire	Moradi	2019	Oceania	Australia	Cross-Sectional	[41]
Endometriosis Impact Scale	Gater	2020	Multiple	Multiple	Mixed methods	[42]
Endometriosis Pain and Bleeding Diary	Deal	2010	North America	United States	Prospective Cohort	[43]
Endometriosis Pain Daily Diary	Van Nooten	2018	Multiple	Multiple	Mixed methods	[44]
Endometriosis Reproductive Health Questionnaire	Namazi	2021	Middle East	Iran	Mixed methods	[45]
Endometriosis Self-Assessment Tool	Cho	2022	Asia	South Korea	Cross-Sectional	[46]
Endometriosis Treatment Satisfaction Questionnaire	Deal	2010	North America	United States	Randomized Controlled Trial	[47]
ENDOPAIN-4D	Fauconnier	2018	Europe	France	Mixed methods	[48]
ENDOPAIN-4D	Puchar	2021	Europe	France	Prospective Cohort	[49]
ENDOPAIN-4D	Ahmadpour	2022	Middle East	Iran	Cross-Sectional	[50]
EndoWheel	As-Sanie	2021	North America	United States	Mixed methods	[51]
Fibroid Symptom Diary	Deal	2011	North America	United States	Mixed methods	[52]
Functional and Emotional Measure of Dysmenorrhea	Li	2012	Asia	China	Cross-Sectional	[53]

Supporting Information for *Measurement of changes to the menstrual cycle: A transdisciplinary systematic review evaluating measure quality and utility for clinical trials* (Mackenzie et al.)

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Injustice Experience Questionnaire-Chronic and the Contribution of Perceived Injustice	Yamada	2019	Asia	Japan	Prospective Cohort	[54]
Mansfield-Voda-Jorgensen Menstrual Bleeding Scale	Mansfield	2004	North America	United States	Prospective Cohort	[55]
Measure compilation (Olliges)	Olliges	2021	Europe	Germany	Case Control	[56]
Menorrhagia Impact Questionnaire	Bushnell	2010	North America	United States	Case Control	[57]
(Menorrhagia) Multi-Attribute Utility Score	Shaw	1998	Europe	United Kingdom	Mixed methods	[58]
(Menorrhagia) Multi-Attribute Utility Score	Habiba	2010	Europe	United Kingdom	Prospective Cohort	[59]
(Menorrhagia) Multi-Attribute Utility Score	Pattison	2011	Europe	United Kingdom	Randomized Controlled Trial	[60]
Menstrual Attitudes Questionnaire	Brooks-Gunn	1980	North America	United States	Cross-Sectional	[61]
Menstrual Attitudes Questionnaire	Bramwell	2002	Europe; Asia	United Kingdom; India	Cross-Sectional	[62]
Menstrual Attitudes Questionnaire	Firat	2009	Europe; Asia	Turkey	Cross-Sectional	[63]
Menstrual Attitudes Questionnaire	Bargiota	2016	Europe	Greece	Cross-Sectional	[64]
Menstrual Attitudes Questionnaire	Kawata	2022	Asia	Nepal	Cross-Sectional	[65]
Menstrual Bleeding Questionnaire	Rezende	2023	South America	Brazil	Prospective Cohort	[66]
Menstrual Bleeding Questionnaire	Matteson	2015	North America	United States	Prospective Cohort; Cross-Sectional	[67]
Menstrual Bleeding Questionnaire	Pike	2021	North America	Canada	Cross-Sectional, Prospective Cohort	[68]
Menstrual Bleeding Questionnaire	Rodpetch	2021	Asia	Thailand	Cross-Sectional	[69]
Menstrual Blood Loss Score Questionnaire	Toxqui	2014	Europe	Spain	Prospective Cohort	[70]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Menstrual Collection	Chimbira	1980	Europe	United Kingdom	Prospective Cohort	[71]
Menstrual Collection	Gleeson	1993	Europe	Ireland	Prospective Cohort	[72]
Menstrual Collection	Gannon	1996	Europe	United Kingdom	Prospective Cohort	[73]
Menstrual Collection	Fraser	2001	Oceania	Australia	Prospective Cohort	[74]
Menstrual Collection	Gudmundsdottir	2009	Europe	Iceland	Prospective Cohort	[75]
Menstrual Distress Questionnaire (Moos)	Moos	1968	North America	United States	Cross-Sectional	[76]
Menstrual Distress Questionnaire (Moos)	Lee	2009	Asia	China	Cross-Sectional	[77]
Menstrual Distress Questionnaire (Vannuccini)	Vannuccini	2021	Europe	Italy	Cross-Sectional	[78]
Menstrual Distress Questionnaire (Vannuccini)	Cassioli	2023	Europe; Oceania	Multiple	Cross-Sectional	[79]
Menstrual Health Instrument	Shin	2018	Asia	South Korea	Mixed methods	[80]
Menstrual Health Seeking Behaviors Questionnaire	Darabi	2018	Middle East	Iran	Cross-Sectional	[81]
Menstrual Hygiene Management Scale	Ramaiya	2020	Asia	India	Mixed methods	[82]
Menstrual Insecurity Tool	Caruso	2020	Asia	India	Mixed methods	[83]
Menstrual Joy Questionnaire	Aubeeluck	2002	Europe	United Kingdom	Cross-Sectional	[84]
Menstrual Practices Questionnaire	Hennegan	2020	Africa	Uganda	Cross-Sectional	[85]
Menstrual Record and Recall	Heath	1999	Oceania	New Zealand	Cross-Sectional	[86]
Menstrual Self-Evaluation Scale	Roberts	2004	North America	United States	Cross-Sectional	[87]
Menstruation-Related Activity Restrictions Questionnaire	Garg	2021	Asia	India	Cross-Sectional	[88]



Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Military Women's Attitudes Toward Menstrual Suppression Scale	Trego	2009	North America	United States	Mixed methods	[89]
New Zealand Survey of Adolescent Girls' Menstruation	Farquhar	2009	Oceania	New Zealand	Cross-Sectional	[90]
Numeric Rating Scale	deArruda	2022	South America	Brazil	Prospective Cohort	[91]
Numeric Rating Scale	Pokrzywinski	2021	North America	Multiple	Randomized Controlled Trial	[92]
Pain Drawing	Rodrigues	2022	South America	Brazil	Cross-Sectional	[93]
Period ImPact and Pain Assessment	Parker	2022	Oceania	Australia	Cross-Sectional	[94]
PERIOD-QOL	Lancastle	2023	Europe	United Kingdom	Cross-Sectional	[95]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Higham	1990	Europe	United Kingdom	Cross-Sectional	[96]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Janssen	1995	Europe	Netherlands	Cross-Sectional	[97]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Barr	1999	Africa	Nigeria	Cross-Sectional	[98]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Reid	2000	Europe	United Kingdom	Prospective Cohort	[99]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Wyatt	2001	Europe	United Kingdom	Prospective Cohort	[100]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Sanchez	2012	North America	United States	Prospective Cohort	[101]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Larsen	2013	North America	United States	Randomized Controlled Trial	[102]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Magnay	2013	Europe	United Kingdom	Laboratory	[103]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Magnay	2014	Europe	United Kingdom	Prospective Cohort	[104]
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms	Hald	2014	Europe	Norway	Retrospective Cohort	[105]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Pictorial Blood Loss Assessment Charts & Menstrual Pictograms and Uterine Fibroid Daily Bleeding Diary	Haberland	2020	Europe	Germany	Randomized Controlled Trial	[106]
Prospective self report, menstrual regularity	Weller	1998	Middle East	Israel	Prospective Cohort	[107]
Quantitative model for menstrual blood loss	Schumacher	2012	Multiple	Multiple	Retrospective Cohort	[108]
Retrospective self-report, last menstrual period	Wegienka	2005	North America	United States	Prospective Cohort	[109]
Retrospective self report, menstrual discomfort	Jukic	2008	North America	United States	Prospective Cohort	[110]
Retrospective self report, menstrual length (Bachand)	Bachand	2009	North America	United States	Prospective Cohort	[111]
Retrospective self report, menstrual length (Small & Jukic)	Jukic	2007	North America	United States	Prospective Cohort	[112]
SAMANTA Questionnaire	Calaf	2020	Europe	Spain	Cross-Sectional	[113]
SAMANTA Questionnaire	Perelló-Capo	2023	Europe	Spain	Prospective Cohort	[114]
Spanish Society of Contraception Quality-of-Life	Pérez-Campos	2011	Europe	Spain	Prospective Cohort	[115]
Squeezing Pain Bulb	Kantarovich	2021	North America	United States	Cross-Sectional	[116]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Spies	2002	North America	United States	Cross-Sectional	[117]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Harding	2008	North America	United States	Prospective Cohort	[118]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Silva	2016	South America	Brazil	Case Control	[119]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Oliveira Brito	2017	South America	Brazil	Cross-Sectional	[120]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Coyne	2017	North America	United States	Randomized Controlled Trial	[121]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Coyne	2019	North America	Multiple	Randomized Controlled Trial	[122]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Yeung	2019	Asia	Hong Kong	Cross-Sectional	[123]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Uterine Fibroid Symptom and Quality of Life Questionnaire	Calaf	2020	Europe	Spain	Cross-Sectional	[124]
Uterine Fibroid Symptom and Quality of Life Questionnaire	Keizer	2021	Europe	Netherlands	Cross-Sectional	[125]
Visual Analogue Scales: Pain	Gerlinger	2012	Europe	Germany	Retrospective Cohort	[126]
Visual Analogue Scales: Pain	Gerlinger	2010	Europe	Multiple	Retrospective Cohort	[127]
Visual Analogue Scales: Bleeding	Perelló	2022	Europe	Spain	Retrospective Cohort	[128]
World Health Organization Disability Assessment Schedule 2.0	deArruda	2023	South America	Brazil	Cross-Sectional	[129]
Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score	Teherán	2018	South America	Colombia	Cross-Sectional	[130]
Working Stressors and Coping Strategies Associated with Menstrual Symptoms Among Nurses	Yu	2021	Asia	Taiwan	Cross-Sectional	[131]
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project Standard Questionnaire	Vitonis	2014	Multiple	Multiple	Other	[132]
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project Standard Questionnaire	Dimentberg	2021	North America	Canada	Prospective Cohort	[133]
<b>Studies validating/evaluating applicable subscales (n=19)</b>						
Low Energy Availability in Females Questionnaire	Melin	2014	Europe	Multiple	Prospective Cohort	[134]
Low Energy Availability in Females Questionnaire	deMaria	2021	South America	Brazil	Prospective Cohort	[135]
Menstrual Cycle-Related Signs and Symptoms Questionnaire	Sutthibut	2021	Asia	Thailand	Cross-Sectional	[136]
Menstrual Symptom Questionnaire	Chesney	1975	North America	United States	Cross-Sectional	[137]
Menstrual Symptom Questionnaire	Nelson	1984	North America	United States	Cross-Sectional	[138]
Menstrual Symptom Questionnaire	Negriff	2009	North America	United States	Cross-Sectional	[139]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Midlife Women's Symptom Index	Im	2006	North America	United States	Cross-Sectional	[140]
ORTHO Birth Control Satisfaction Assessment Tool	Mathias	2006	North America	United States	Mixed methods	[141]
ORTHO Birth Control Satisfaction Assessment Tool	Colwell	2006	North America	United States	Cross-Sectional	[142]
Ovulation and Menstruation Health Questionnaire	Mahalingaiah	2020	North America	United States	Mixed methods	[143]
Polycystic Ovary Syndrome Quality of Life Scale	Saei Ghare Naz	2023	Middle East	Iran	Mixed methods	[144]
Polycystic Ovary Syndrome Quality of Life Scale	Cronin	1998	North America	United States	Mixed methods	[145]
Polycystic Ovary Syndrome Quality of Life Scale	Jones	2004	Europe	United Kingdom	Cross-Sectional	[146]
Polycystic Ovary Syndrome Quality of Life Scale	Guyatt	2004	Europe	United Kingdom	Randomized Controlled Trial	[147]
Polycystic Ovary Syndrome Quality of Life Scale	Jedel	2008	Europe	Sweden	Randomized Controlled Trial	[148]
Polycystic Ovary Syndrome Quality of Life Scale	Bazarganipour	2012	Middle East	Iran	Cross-Sectional	[149]
Polycystic Ovary Syndrome Quality of Life Scale	Bazarganipour	2013	Middle East	Iran	Cross-Sectional	[150]
Polycystic Ovary Syndrome Quality of Life Scale	Chung	2016	Asia	China	Cross-Sectional	[151]
Women Shift Workers Reproductive Health Questionnaire	Nikpour	2020	Middle East	Iran	Mixed methods	[152]
<b>Studies validating/evaluating instruments with applicable items/questions (n=14)</b>						
Adolescent Menstrual Attitude Questionnaire	Morse	1993	North America	Canada	Not assessed	[153]
Adolescent Menstrual Attitude Questionnaire	Morse	1993	North America	Canada	Not assessed	[154]
CARDIA Women's Reproductive Health Questionnaire	Whitham	2013	North America	United States	Not assessed	[155]

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Clinical Tool for Diagnosis of PCOS	Pedersen	2007	North America	Canada	Not assessed	[156]
Clinically Validated Scores for Endometriosis Diagnosis	Chapron	2022	Europe	France	Not assessed	[157]
Experience Sampling Method	van Barneveld	2023	Europe	Netherlands	Not assessed	[158]
Immune Thrombocytopenic Purpura Patient Assessment Questionnaire	Mathias	2007	Multiple	Multiple	Not assessed	[159]
Painful Periods Screening Tool	DiBenedetti	2018	North America	United States	Not assessed	[160]
Polycystic Ovary Syndrome Questionnaire-50	Nasiri-Amiri	2016	Middle East	Iran	Not assessed	[161]
Polycystic Ovary Syndrome Questionnaire-50	Stevanovic	2019	Europe	Serbia	Not assessed	[162]
Self-Efficacy in Addressing Menstrual Needs Scale	Hunter	2022	Asia	Bangladesh	Not assessed	[163]
Stellenbosch Endometriosis Quality of Life Measure	Rizwana	2018	Africa	South Africa	Not assessed	[164]
Structured Endometriosis Questionnaire	Hackethal	2011	Europe	Germany	Not assessed	[165]
The International Spinal Cord Injury Female Sexual and Reproductive Function	Alexander	2011	Multiple	Multiple	Not assessed	[166]
<b>Studies validating/evaluating general instruments in menstruating populations (n=8)</b>						
Health Related Productivity Questionnaire	Pokrzywinski	2020	Multiple	Multiple	Not assessed	[167]
Patient-Generated Index of Quality of Life	Ruta	1999	Europe	United Kingdom	Not assessed	[168]
Patient-Reported Outcomes Measurement Information System	Schneider	2013	North America	United States	Not assessed	[169]
Patient-Reported Outcomes Measurement Information System	Pokrzywinski	2020	North America	Multiple	Not assessed	[170]
Survey of Pain Attitudes	Ferreira-Valente	2019	Europe	Portugal	Not assessed	[171]
Women's Health Questionnaire	Hunter	1992	Europe	United Kingdom	Not assessed	[172]

Supporting Information for *Measurement of changes to the menstrual cycle: A transdisciplinary systematic review evaluating measure quality and utility for clinical trials* (Mackenzie et al.)

Measures being evaluated/validated	First author	Year	Region	Country	Study Design	Ref.
Women's Health Questionnaire	Hunter	2000	Europe	United Kingdom	Not assessed	[173]
Women's Health Questionnaire	Colantonio	2011	North America	Canada	Not assessed	[174]

## References

1. Ruta DA, Garratt AM, Chadha YC, Flett GM, Hall MH, Russell IT. Assessment of patients with menorrhagia: How valid is a structured clinical history as a measure of health status? *Quality of Life Research*. 1995;4: 33–40. doi:10.1007/BF00434381
2. Abu-Rafea BF, Vilos GA, Al Jasser RS, Al Anazy RM, Javaid K, Al-Mandeel HM. Linguistic and clinical validation of the Arabic-translated Aberdeen Menorrhagia Severity Scale as an indicator of quality of life for women with abnormal uterine bleeding. *Saudi Med J*. 2012;33: 869–74. Available: <http://www.ncbi.nlm.nih.gov/pubmed/22886120>
3. Ching-Hsing H, Meei-Ling G, Hsin-Chun M, Chung-Yi L. The development and psychometric testing of a self-care scale for dysmenorrhic adolescents. *The journal of nursing research*. 2004;12: 119–30. doi:10.1097/01.jnr.0000387495.01557.aa
4. Wong CL, Ip WY, Choi KC, Shiu TY. Translation and validation of the Chinese-Cantonese version of the Adolescent Dysmenorrhic Self-Care Scale in Hong Kong adolescent girls. *J Clin Nurs*. 2013;22: 1510–1520. doi:10.1111/jocn.12019
5. van Eijkeren MA, Scholten PC, Christiaens GC, Alsbach GP, Haspels AA. The alkaline hematin method for measuring menstrual blood loss—a modification and its clinical use in menorrhagia. *Eur J Obstet Gynecol Reprod Biol*. 1986;22: 345–51. doi:10.1016/0028-2243(86)90124-3
6. Small CM, Manatunga AK, Marcus M. Validity of Self-Reported Menstrual Cycle Length. *Ann Epidemiol*. 2007;17: 163–170. doi:10.1016/j.annepidem.2006.05.005
7. Hudgens S, Gauthier M, Hunsche E, Kang J, Li Y, Scippa K, et al. Development of the Bleeding and Pelvic Discomfort Scale for Use in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids. *Value in Health*. 2022;25. doi:10.1016/j.jval.2022.06.005
8. Paramsothy P, Harlow SD, Elliott MR, Lisabeth LD, Crawford SL, Randolph JF. Classifying menopause stage by menstrual calendars and annual interviews: need for improved questionnaires. *Menopause*. 2013;20: 727–35. doi:10.1097/GME.0b013e3182825ff2
9. Johannes CB, Crawford SL, Woods J, Goldstein RB, Tran D, Mehrotra S, et al. An Electronic Menstrual Cycle Calendar: Comparison of Data Quality With a Paper Version. *Menopause*. 2000;7: 200–208. doi:10.1097/00042192-200007030-00011
10. Nguyen AM, Humphrey L, Kitchen H, Rehman T, Norquist JM. A qualitative study to develop a patient-reported outcome for dysmenorrhea. *Quality of Life Research*. 2015;24: 181–191. doi:10.1007/s11136-014-0755-z
11. Nguyen AM, Arbuckle R, Korver T, Chen F, Taylor B, Turnbull A, et al. Psychometric validation of the dysmenorrhea daily diary (DysDD): a patient-reported outcome for dysmenorrhea. *Quality of Life Research*. 2017;26: 2041–2055. doi:10.1007/s11136-017-1562-0
12. Chen CX, Murphy T, Ofner S, Yahng L, Krombach P, LaPradd M, et al. Development and Testing of the Dysmenorrhea Symptom Interference (DSI) Scale. *West J Nurs Res*. 2021;43: 364–373. doi:10.1177/0193945920942252

13. Gray TG, Moores KL, James E, Connor ME, Jones GL, Radley SC. Development and initial validation of an electronic personal assessment questionnaire for menstrual, pelvic pain and gynaecological hormonal disorders (ePAQ-MPH). *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2019;238: 148–156. doi:10.1016/j.ejogrb.2019.05.024
14. Guan Y, Nguyen AM, Wratten S, Randhawa S, Weaver J, Arbelaez F, et al. The endometriosis daily diary: qualitative research to explore the patient experience of endometriosis and inform the development of a patient-reported outcome (PRO) for endometriosis-related pain. *J Patient Rep Outcomes*. 2022;6: 5. doi:10.1186/s41687-021-00409-8
15. Wyrwich KW, O'Brien CF, Soliman AM, Chwalisz K. Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain. *Reproductive Sciences*. 2018;25: 1567–1576. doi:10.1177/1933719118789509
16. Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C. Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. *Obstetrics and gynecology*. 2001;98: 258–64. doi:10.1016/s0029-7844(01)01433-8
17. Mengarda CV, Passos EP, Picon P, Costa AF, Picon PD. Validação de versão para o português de questionário sobre qualidade de vida para mulher com endometriose (Endometriosis Health Profile Questionnaire - EHP-30). *Revista Brasileira de Ginecologia e Obstetrícia*. 2008;30: 384–392. doi:10.1590/S0100-72032008000800003
18. Grundström H, Rauden A, Olovsson M. Cross-cultural adaptation of the Swedish version of Endometriosis Health Profile-30. *J Obstet Gynaecol (Lahore)*. 2020;40: 969–973. doi:10.1080/01443615.2019.1676215
19. Grundström H, Rauden A, Wikman P, Olovsson M. Psychometric evaluation of the Swedish version of the 30-item endometriosis health profile (EHP-30). *BMC Womens Health*. 2020;20: 204. doi:10.1186/s12905-020-01067-6
20. Jones G, Jenkinson C, Kennedy S. Evaluating the responsiveness of the endometriosis health profile questionnaire: The EHP-30. *Quality of Life Research*. 2004;13: 705–713. doi:10.1023/B:QURE.0000021316.79349.af
21. Jenkinson C, Kennedy S, Jones G. Evaluation of the American version of the 30-item Endometriosis Health Profile (EHP-30). *Quality of Life Research*. 2008;17: 1147–1152. doi:10.1007/s11136-008-9403-9
22. Hansen KE, Lambek R, Røssaak K, Egekvist AG, Marschall H, Forman A, et al. Health-related quality of life in women with endometriosis: psychometric validation of the Endometriosis Health Profile 30 questionnaire using confirmatory factor analysis. *Hum Reprod Open*. 2022;2022. doi:10.1093/hropen/hoab042
23. Khong S-Y, Lam A, Luscombe G. Is the 30-item Endometriosis Health Profile (EHP-30) suitable as a self-report health status instrument for clinical trials? *Fertil Steril*. 2010;94: 1928–1932. doi:10.1016/j.fertnstert.2010.01.047



24. Verket NJ, Andersen MH, Sandvik L, Tanbo TG, Qvigstad E. Lack of cross-cultural validity of the Endometriosis Health Profile-30. *J Endometr Pelvic Pain Disord*. 2018;10: 107–115. doi:10.1177/2284026518780638
25. Jones G, Jenkinson C, Taylor N, Mills A, Kennedy S. Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire. *Human Reproduction*. 2006;21: 2686–2693. doi:10.1093/humrep/del231
26. van de Burgt TJM, Hendriks JCM, Kluivers KB. Quality of life in endometriosis: evaluation of the Dutch-version Endometriosis Health Profile–30 (EHP-30). *Fertil Steril*. 2011;95: 1863–1865. doi:10.1016/j.fertnstert.2010.11.009
27. van de Burgt TJM, Kluivers KB, Hendriks JCM. Responsiveness of the Dutch Endometriosis Health Profile-30 (EHP-30) questionnaire. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2013;168: 92–94. doi:10.1016/j.ejogrb.2012.12.037
28. Wickström KW, Spira J, Edelstam G. Responsiveness of the Endometriosis Health Profile-30 questionnaire in a Swedish sample: an observational study. *Clin Exp Obstet Gynecol*. 2017;44: 413–418. doi:10.12891/ceog3599.2017
29. Nojomi M, Bijari B, Akhbari R, Kashanian M. The Assessment of Reliability and Validity of Persian Version of the Endometriosis Health Profile (EHP-30). *Iran J Med Sci*. 2011;36: 84–9. Available: <http://www.ncbi.nlm.nih.gov/pubmed/23358588>
30. Mansor M, Chong MC, Chui PL, Hamdan M, Basha MAMK. The psychometric properties test of the Malay version of the endometriosis health profile-30. *Saudi Med J*. 2023;44. doi:10.15537/smj.2023.44.9.20230228
31. Maiorana A, Scafidi Fonti GM, Audino P, Rosini R, Alio L, Oliveri AM, et al. The role of EHP-30 as specific instrument to assess the quality of life of Italian women with endometriosis. *Minerva Ginecol*. 2012;64: 231–8. Available: <http://www.ncbi.nlm.nih.gov/pubmed/22635018>
32. Marí-Alexandre J, García-Oms J, Agababyan C, Belda-Montesinos R, Royo-Bolea S, Varo-Gómez B, et al. Toward an improved assessment of quality of life in endometriosis: evaluation of the Spanish version of the Endometriosis Health Profile 30. *Journal of Psychosomatic Obstetrics and Gynecology*. 2022;43. doi:10.1080/0167482X.2020.1795827
33. Nogueira-Silva C, Costa P, Martins C, Barata S, Alho C, Calhaz-Jorge C, et al. Validação da Versão Portuguesa do Questionário EHP-30 (The Endometriosis Health Profile-30). *Acta Med Port*. 2015;28: 347–356. doi:10.20344/amp.5778
34. Chauvet P, Auclair C, Mourgues C, Canis M, Gerbaud L, Bourdel N. Psychometric properties of the French version of the Endometriosis Health Profile-30, a health-related quality of life instrument. *J Gynecol Obstet Hum Reprod*. 2017;46: 235–242. doi:10.1016/j.jogoh.2017.02.004
35. Jia S-Z, Leng J-H, Sun P-R, Lang J-H. Translation and psychometric evaluation of the simplified Chinese-version Endometriosis Health Profile-30. *Human Reproduction*. 2013;28: 691–697. doi:10.1093/humrep/des426

36. Jones G, Jenkinson C, Kennedy S. Evaluating the responsiveness of the Endometriosis Health Profile Questionnaire: the EHP-30. *Qual Life Res.* 2004;13: 705–713. doi:10.1023/B:QURE.0000021316.79349.af
37. Fauconnier A, Huchon C, Chaillou L, Aubry G, Renouvel F, Panel P. Development of a French version of the Endometriosis Health Profile 5 (EHP-5): cross-cultural adaptation and psychometric evaluation. *Quality of Life Research.* 2017;26: 213–220. doi:10.1007/s11136-016-1346-y
38. Aubry G, Panel P, Thiollier G, Huchon C, Fauconnier A. Measuring health-related quality of life in women with endometriosis: comparing the clinimetric properties of the Endometriosis Health Profile-5 (EHP-5) and the EuroQol-5D (EQ-5D). *Human Reproduction.* 2017;32: 1258–1269. doi:10.1093/humrep/dex057
39. Mikuš M, Matak L, Vujić G, Škegro B, Škegro I, Augustin G, et al. The short form endometriosis health profile questionnaire (EHP-5): psychometric validity assessment of a Croatian version. *Arch Gynecol Obstet.* 2023;307: 87–92. doi:10.1007/s00404-022-06691-1
40. Selcuk S, Sahin S, Demirci O, Aksoy B, Eroglu M, Ay P, et al. Translation and validation of the Endometriosis Health Profile (EHP-5) in patients with laparoscopically diagnosed endometriosis. *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 2015;185: 41–44. doi:10.1016/j.ejogrb.2014.11.039
41. Moradi M, Parker M, Sneddon A, Lopez V, Ellwood D. The Endometriosis Impact Questionnaire (EIQ): a tool to measure the long-term impact of endometriosis on different aspects of women's lives. *BMC Womens Health.* 2019;19: 64. doi:10.1186/s12905-019-0762-x
42. Gater A, Taylor F, Seitz C, Gerlinger C, Wichmann K, Haberland C. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). *J Patient Rep Outcomes.* 2020;4: 13. doi:10.1186/s41687-020-0177-3
43. Deal LS, DiBenedetti D, Williams VS, Fehnel SE. The development and validation of the daily electronic Endometriosis Pain and Bleeding Diary. *Health Qual Life Outcomes.* 2010;8: 64. doi:10.1186/1477-7525-8-64
44. van Nooten FE, Cline J, Elash CA, Paty J, Reaney M. Development and content validation of a patient-reported endometriosis pain daily diary. *Health Qual Life Outcomes.* 2018;16: 3. doi:10.1186/s12955-017-0819-1
45. Namazi M, Zareiyan A, Jafarabadi M, Behboodi Moghadam Z. Endometriosis reproductive health questionnaire (ERHQ): A self-administered questionnaire to measure the reproductive health in women with endometriosis. *J Gynecol Obstet Hum Reprod.* 2021;50: 101860. doi:10.1016/j.jogoh.2020.101860
46. Cho H-H, Yoon Y-S. Development of an endometriosis self-assessment tool for patient. *Obstet Gynecol Sci.* 2022;65: 256–265. doi:10.5468/ogs.21252

47. Deal LS, Williams VSL, DiBenedetti DB, Fehnel SE. Development and psychometric evaluation of the Endometriosis Treatment Satisfaction Questionnaire. *Quality of Life Research*. 2010;19: 899–905. doi:10.1007/s11136-010-9640-6
48. Fauconnier A, Staraci S, Darai E, Descamps P, Nisolle M, Panel P, et al. A self-administered questionnaire to measure the painful symptoms of endometriosis: Results of a modified DELPHI survey of patients and physicians. *J Gynecol Obstet Hum Reprod*. 2018;47: 69–79. doi:10.1016/j.jogoh.2017.11.003
49. Puchar A, Panel P, Oppenheimer A, Du Cheyron J, Fritel X, Fauconnier A. The ENDOPAIN 4D Questionnaire: A New Validated Tool for Assessing Pain in Endometriosis. *J Clin Med*. 2021;10: 3216. doi:10.3390/jcm10153216
50. Ahmadpour P, Jahangiry L, Bani S, Iravani M, Mirghafourvand M. Validation of the Iranian version of the ENDOPAIN-4D questionnaire for measurement of painful symptoms of endometriosis. *J Obstet Gynaecol (Lahore)*. 2022;42. doi:10.1080/01443615.2022.2049726
51. As-Sanie S, Laufer MR, Missmer SA, Murji A, Vincent K, Eichner S, et al. Development of a visual, patient-reported tool for assessing the multi-dimensional burden of endometriosis. *Curr Med Res Opin*. 2021;37: 1443–1449. doi:10.1080/03007995.2021.1929896
52. Deal LS, Williams VSL, Fehnel SE. Development of an Electronic Daily Uterine Fibroid Symptom Diary. *The Patient: Patient-Centered Outcomes Research*. 2011;4: 31–44. doi:10.2165/11537290-000000000-00000
53. Li L, Huangfu L, Chai H, He W, Song H, Zou X, et al. Development of a functional and emotional measure of dysmenorrhea (FEMD) in Chinese university women. *Health Care Women Int*. 2012;33: 97–108. doi:10.1080/07399332.2011.603863
54. Yamada K, Adachi T, Kubota Y, Takeda T, Iseki M. Developing a Japanese version of the Injustice Experience Questionnaire-chronic and the contribution of perceived injustice to severity of menstrual pain: a web-based cross-sectional study. *Biopsychosoc Med*. 2019;13: 17. doi:10.1186/s13030-019-0158-z
55. Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. *Women’s Health Issues*. 2004;14: 242–247. doi:10.1016/j.whi.2004.07.005
56. Olliges E, Bobinger A, Weber A, Hoffmann V, Schmitz T, Popovici RM, et al. The Physical, Psychological, and Social Day-to-Day Experience of Women Living With Endometriosis Compared to Healthy Age-Matched Controls—A Mixed-Methods Study. *Front Glob Womens Health*. 2021;2: 767114. doi:10.3389/fgwh.2021.767114
57. Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. *Curr Med Res Opin*. 2010;26: 2745–55. doi:10.1185/03007995.2010.532200
58. Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. *BJOG*. 1998;105: 1155–1159. doi:10.1111/j.1471-0528.1998.tb09968.x

59. Habiba M, Julian S, Taub N, Clark M, Rashid A, Baker R, et al. Limited role of multi-attribute utility scale and SF-36 in predicting management outcome of heavy menstrual bleeding. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2010;148: 81–85. doi:10.1016/j.ejogrb.2009.09.021
60. Pattison H, Daniels J, Kai J, Gupta J. The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis. *BJOG*. 2011;118: 1528–1531. doi:10.1111/j.1471-0528.2011.03057.x
61. Brooks-Gunn J, Ruble DN. The menstrual attitude questionnaire. *Psychosom Med*. 1980;42: 503–12. doi:10.1097/00006842-198009000-00005
62. Bramwell RS, Biswas EL, Anderson C. Using the Menstrual Attitude Questionnaire with a British and an Indian sample. *J Reprod Infant Psychol*. 2002;20: 159–170. doi:10.1080/026468302760270818
63. Firat MZ, Kulakaç Ö, Öncel S, Akcan A. Menstrual Attitude Questionnaire: confirmatory and exploratory factor analysis with Turkish samples. *J Adv Nurs*. 2009;65: 652–662. doi:10.1111/j.1365-2648.2008.04919.x
64. Bargiota S, Bonotis K, Garyfallos G, Messinis I, Angelopoulos N. The Psychometric Properties of Menstrual Attitudes Questionnaire: A validity Study in Greek Women. *Int J Innov Res Sci Eng Technol*. 2016;5: 1754–1765. doi:10.15680/IJIRSET.2016.0502109
65. Kawata R, Endo M, Rai SK, Ohashi K. Development of a scale to evaluate negative menstrual attitudes among Nepalese women. *Reprod Health*. 2022;19: 120. doi:10.1186/s12978-022-01426-6
66. Rezende GP, Brito LGO, Gomes DAY, Souza LM de, Polo S, Benetti-Pinto CL. Assessing a cut-off point for the diagnosis of abnormal uterine bleeding using the Menstrual Bleeding Questionnaire (MBQ): a validation and cultural translation study with Brazilian women. *Sao Paulo Med J*. 2023;142: e2022539. doi:10.1590/1516-3180.2022.0539.R2.100423
67. Matteson KA, Scott DM, Raker CA, Clark MA. The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. *BJOG*. 2015;122: 681–9. doi:10.1111/1471-0528.13273
68. Pike M, Chopek A, NL Y, Usuba K, MJ B, McLaughlin R, et al. Quality of life in adolescents with heavy menstrual bleeding: Validation of the Adolescent Menstrual Bleeding Questionnaire (aMBQ). *Res Pract Thromb Haemost*. 2021;5: e12615. doi:10.1002/rth2.12615
69. Rodpetch T, Manonai J, Angchaisuksiri P, Boonyawat K. A quality-of-life questionnaire for heavy menstrual bleeding in Thai women receiving oral antithrombotics: Assessment of the translated Menstrual Bleeding Questionnaire. *Res Pract Thromb Haemost*. 2021;5: e12617. doi:10.1002/rth2.12617
70. Toxqui L, Pérez-Granados AM, Blanco-Rojo R, Wright I, Vaquero MP. A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and

- gynecological parameters in young women. *BMC Womens Health*. 2014;14: 71.  
doi:10.1186/1472-6874-14-71
71. Chimbira TH, Anderson AB, Turnbull A c. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. *Br J Obstet Gynaecol*. 1980;87: 603–9.  
doi:10.1111/j.1471-0528.1980.tb05013.x
  72. Gleeson N, Devitt M, Buggy F, Bonnar J. Menstrual Blood Loss Measurement with Gynaeseal. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 1993;33: 79–80.  
doi:10.1111/j.1479-828X.1993.tb02061.x
  73. Gannon MJ, Day P, Hammadih N, Johnson N. A new method for measuring menstrual blood loss and its use in screening women before endometrial ablation. *BJOG*. 1996;103: 1029–1033.  
doi:10.1111/j.1471-0528.1996.tb09556.x
  74. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. *Obstetrics and gynecology*. 2001;98: 806–14.  
doi:10.1016/s0029-7844(01)01581-2
  75. Gudmundsdottir BR, Hjaltalin EF, Bragadottir G, Hauksson A, Geirsson RT, Onundarson PT. Quantification of menstrual flow by weighing protective pads in women with normal, decreased or increased menstruation. *Acta Obstet Gynecol Scand*. 2009;88: 275–9.  
doi:10.1080/00016340802673162
  76. Moos RH. The development of a menstrual distress questionnaire. *Psychosom Med*. 1968;30: 853–67. doi:10.1097/00006842-196811000-00006
  77. Lee AM, So-Kum Tang C, Chong C. A culturally sensitive study of premenstrual and menstrual symptoms among Chinese women. *Journal of Psychosomatic Obstetrics & Gynecology*. 2009;30: 105–114. doi:10.1080/01674820902789241
  78. Vannuccini S, Rossi E, Cassioli E, Cirone D, Castellini G, Ricca V, et al. Menstrual Distress Questionnaire (MEDI-Q): a new tool to assess menstruation-related distress. *Reprod Biomed Online*. 2021;43: 1107–1116. doi:10.1016/j.rbmo.2021.08.029
  79. Cassioli E, Rossi E, Melani G, Faldi M, Rellini AH, Wyatt RB, et al. The menstrual distress questionnaire (MEDI-Q): reliability and validity of the English version. *Gynecological Endocrinology*. 2023;39. doi:10.1080/09513590.2023.2227275
  80. Shin H, Park Y-J, Cho I. Development and psychometric validation of the Menstrual Health Instrument (MHI) for adolescents in Korea. *Health Care Women Int*. 2018;39: 1090–1109.  
doi:10.1080/07399332.2017.1423487
  81. Darabi F, Yaseri M, Rohban A, Khalajabadi-Farahani F. Development and Psychometric Properties of Menstrual Health Seeking Behaviors Questionnaire (MHSBQ-42) in Female Adolescents. *J Reprod Infertil*. 2018;19: 229–236. Available: <http://www.ncbi.nlm.nih.gov/pubmed/30746338>

82. Ramaiya A, Sood S. What are the psychometric properties of a menstrual hygiene management scale: a community-based cross-sectional study. *BMC Public Health*. 2020;20: 525. doi:10.1186/s12889-020-08627-3
83. Caruso BA, Portela G, McManus S, Clasen T. Assessing Women's Menstruation Concerns and Experiences in Rural India: Development and Validation of a Menstrual Insecurity Measure. *Int J Environ Res Public Health*. 2020;17: 3468. doi:10.3390/ijerph17103468
84. Aubeeluck A, Maguire M. The Menstrual Joy Questionnaire Items Alone Can Positively Prime Reporting of Menstrual Attitudes and Symptoms. *Psychol Women Q*. 2002;26: 160–162. doi:10.1111/1471-6402.00054
85. Hennegan J, Nansubuga A, Akullo A, Smith C, Schwab KJ. The Menstrual Practices Questionnaire (MPQ): development, elaboration, and implications for future research. *Glob Health Action*. 2020;13: 1829402. doi:10.1080/16549716.2020.1829402
86. Heath AL, Skeaff CM, Gibson RS. Validation of a questionnaire method for estimating extent of menstrual blood loss in young adult women. *J Trace Elem Med Biol*. 1999;12: 231–5. doi:10.1016/S0946-672X(99)80063-7
87. Roberts T-A. Female Trouble: The Menstrual Self-Evaluation Scale and Women's Self-Objectification. *Psychol Women Q*. 2004;28: 22–26. doi:10.1111/j.1471-6402.2004.00119.x
88. Garg S, Marimuthu Y, Bhatnagar N, Singh MmC, Borle A, Basu S, et al. Development and validation of a menstruation-related activity restriction questionnaire among adolescent girls in urban resettlement colonies of Delhi. *Indian Journal of Community Medicine*. 2021;46: 57. doi:10.4103/ijcm.IJCM\_183\_20
89. Trego LL. Development of the Military Women's Attitudes Toward Menstrual Suppression Scale: From Construct Definition to Pilot Testing. *J Nurs Meas*. 2009;17: 45–72. doi:10.1891/1061-3749.17.1.45
90. Farquhar CM, Roberts H, Okonkwo QL, Stewart AW. A pilot survey of the impact of menstrual cycles on adolescent health. *Aust N Z J Obstet Gynaecol*. 2009;49: 531–6. doi:10.1111/j.1479-828X.2009.01062.x
91. de Arruda GT, Driusso P, Rodrigues JC, de Godoy AG, Avila MA. Numerical rating scale for dysmenorrhea-related pain: a clinimetric study. *Gynecological Endocrinology*. 2022;38. doi:10.1080/09513590.2022.2099831
92. Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. *Fertil Steril*. 2021;115: 423–430. doi:10.1016/j.fertnstert.2020.07.013
93. Rodrigues JC, Avila MA, dos Reis FJJ, Carlessi RM, Godoy AG, Arruda GT, et al. 'Painting my pain': the use of pain drawings to assess multisite pain in women with primary dysmenorrhea. *BMC Womens Health*. 2022;22. doi:10.1186/s12905-022-01945-1

94. Parker MA, Kent AL, Sneddon A, Wang J, Shadbolt B. The Menstrual Disorder of Teenagers (MDOT) Study No. 2: Period ImPact and Pain Assessment (PIPPA) Tool Validation in a Large Population-Based Cross-Sectional Study of Australian Teenagers. *J Pediatr Adolesc Gynecol*. 2022;35: 30–38. doi:10.1016/j.jpag.2021.06.003
95. Lancaster D, Kopp Kallner H, Hale G, Wood B, Ashcroft L, Driscoll H. Development of a brief menstrual quality of life measure for women with heavy menstrual bleeding. *BMC Womens Health*. 2023;23. doi:10.1186/s12905-023-02235-0
96. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. *Br J Obstet Gynaecol*. 1990;97: 734–9. doi:10.1111/j.1471-0528.1990.tb16249.x
97. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. *Obstetrics and gynecology*. 1995;85: 977–82. doi:10.1016/0029-7844(95)00062-V
98. Barr F, Brabin L, Agbaje O. A pictorial chart for managing common menstrual disorders in Nigerian adolescents. *Int J Gynaecol Obstet*. 1999;66: 51–3. doi:10.1016/s0020-7292(99)00025-9
99. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. *BJOG*. 2000;107: 320–322. doi:10.1111/j.1471-0528.2000.tb13225.x
100. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PMS. Determination of total menstrual blood loss. *Fertil Steril*. 2001;76: 125–131. doi:10.1016/S0015-0282(01)01847-7
101. Sanchez J, Andrabi S, Bercaw JL, Dietrich JE. Quantifying the PBAC in a Pediatric and Adolescent Gynecology Population. *Pediatr Hematol Oncol*. 2012;29: 479–484. doi:10.3109/08880018.2012.699165
102. Larsen L, Coyne K, Chwalisz K. Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. *Reprod Sci*. 2013;20: 680–7. doi:10.1177/1933719112463252
103. Magnay JL, Nevatte TM, Seitz C, O'Brien S. A new menstrual pictogram for use with feminine products that contain superabsorbent polymers. *Fertil Steril*. 2013;100: 1715-21.e1–4. doi:10.1016/j.fertnstert.2013.08.028
104. Magnay JL, Nevatte TM, O'Brien S, Gerlinger C, Seitz C. Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers. *Fertil Steril*. 2014;101: 515–22. doi:10.1016/j.fertnstert.2013.10.051
105. Hald K, Lieng M. Assessment of Periodic Blood Loss: Interindividual and Intraindividual Variations of Pictorial Blood Loss Assessment Chart Registrations. *J Minim Invasive Gynecol*. 2014;21: 662–668. doi:10.1016/j.jmig.2014.01.015
106. Haberland C, Filonenko A, Seitz C, Börner M, Gerlinger C, Doll H, et al. Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies. *J Patient Rep Outcomes*. 2020;4: 97. doi:10.1186/s41687-020-00263-0

107. Weller A, Weller L. Assessment of menstrual regularity and irregularity using self-reports and objective criteria. *Journal of Psychosomatic Obstetrics & Gynecology*. 1998;19: 111–116. doi:10.3109/01674829809048504
108. Schumacher U, Schumacher J, Mellinger U, Gerlinger C, Wienke A, Endrikat J. Estimation of menstrual blood loss volume based on menstrual diary and laboratory data. *BMC Womens Health*. 2012;12: 24. doi:10.1186/1472-6874-12-24
109. Wegienka G, Baird DD. A comparison of recalled date of last menstrual period with prospectively recorded dates. *J Womens Health (Larchmt)*. 2005;14: 248–52. doi:10.1089/jwh.2005.14.248
110. Jukic AMZ, Weinberg CR, Baird DD, Hornsby PP, Wilcox AJ. Measuring Menstrual Discomfort. *Epidemiology*. 2008;19: 846–850. doi:10.1097/EDE.0b013e318187ac9e
111. Bachand AM, Cragin LA, Reif JS. Reliability of Retrospectively Assessed Categorical Menstrual Cycle Length Data. *Ann Epidemiol*. 2009;19: 501–503. doi:10.1016/j.annepidem.2009.03.015
112. Jukic AMZ, Weinberg CR, Wilcox AJ, McConnaughey DR, Hornsby P, Baird DD. Accuracy of Reporting of Menstrual Cycle Length. *Am J Epidemiol*. 2007;167: 25–33. doi:10.1093/aje/kwm265
113. Calaf J, Cancelo MJ, Andeyro M, Jiménez JM, Perelló J, Correa M, et al. Development and Psychometric Validation of a Screening Questionnaire to Detect Excessive Menstrual Blood Loss That Interferes in Quality of Life: The SAMANTA Questionnaire. *J Womens Health (Larchmt)*. 2020;29: 1021–1031. doi:10.1089/jwh.2018.7446
114. Perelló-Capo J, Rius-Tarruella J, Andeyro-García M, Calaf-Alsina J. Sensitivity to Change of the SAMANTA Questionnaire, a Heavy Menstrual Bleeding Diagnostic Tool, after 1 Year of Hormonal Treatment. *J Womens Health*. 2023;32. doi:10.1089/jwh.2022.0155
115. Pérez-Campos E, Dueñas JL, de la Viuda E, Gómez MÁ, Lertxundi R, Sánchez-Borrego R, et al. Development and validation of the SEC-QOL questionnaire in women using contraceptive methods. *Value Health*. 2011;14: 892–9. doi:10.1016/j.jval.2011.08.1729
116. Kantarovich D, Dillane KE, Garrison EF, Oladosu FA, Schroer MS, Roth GE, et al. Development and validation of a real-time method characterizing spontaneous pain in women with dysmenorrhea. *Journal of Obstetrics and Gynaecology Research*. 2021;47: 1472–1480. doi:10.1111/jog.14663
117. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. *Obstetrics and gynecology*. 2002;99: 290–300. doi:10.1016/s0029-7844(01)01702-1
118. Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). *Health Qual Life Outcomes*. 2008;6: 99. doi:10.1186/1477-7525-6-99
119. Silva R, Gomes M, Castro R, Bonduki C, Girão M. Uterine Fibroid Symptom - Quality of Life questionnaire translation and validation into Brazilian Portuguese. *Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics*. 2016;38: 518–523. doi:10.1055/s-0036-1593833



120. Oliveira Brito LG, Malzone-Lott DA, Sandoval Fagundes MF, Magnani PS, Fernandes Arouca MA, Poli-Neto OB, et al. Translation and validation of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire for the Brazilian Portuguese language. *Sao Paulo Medical Journal*. 2017;135: 107–115. doi:10.1590/1516-3180.2016.0223281016
121. Coyne KS, Soliman AM, Margolis MK, Thompson CL, Chwalisz K. Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire. *Curr Med Res Opin*. 2017;33: 193–200. doi:10.1080/03007995.2016.1248382
122. Coyne KS, Harrington A, Currie BM, Chen J, Gillard P, Spies JB. Psychometric validation of the 1-month recall Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL). *J Patient Rep Outcomes*. 2019;3: 57. doi:10.1186/s41687-019-0146-x
123. Yeung S, Kwok JW, Law S, Chung JP, Chan SS. Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire: a Chinese translation and validation study. *Hong Kong Medical Journal*. 2019;25: 453–459. doi:10.12809/hkmj198064
124. Calaf J, Palacios S, Cristóbal I, Cañete ML, Monleón J, Fernández J, et al. Validation of the Spanish version of the Uterine Fibroid Symptom and Quality of Life (UFS-QoL) questionnaire in women with uterine myomatosis. *Med Clin (Barc)*. 2020;154: 207–213. doi:10.1016/j.medcli.2019.05.027
125. Keizer AL, van Kesteren PJM, Terwee C, de Lange ME, Hehenkamp WJK, Kok HS. Uterine Fibroid Symptom and Quality of Life questionnaire (UFS-QOL NL) in the Dutch population: a validation study. *BMJ Open*. 2021;11: e052664. doi:10.1136/bmjopen-2021-052664
126. Gerlinger C, Schumacher U, Wentzack R, Uhl-Hochgräber K, Solomayer EF, Schmitz H, et al. How can we measure endometriosis-associated pelvic pain? *J Endometr*. 2012;4: 109–116. doi:10.5301/JE.2012.9725
127. Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. *Health Qual Life Outcomes*. 2010;8: 138. doi:10.1186/1477-7525-8-138
128. Perelló J, Pujol P, Pérez M, Artés M, Calaf J. Heavy Menstrual Bleeding-Visual Analog Scale, an Easy-to-Use Tool for Excessive Menstrual Blood Loss That Interferes with Quality-of-Life Screening in Clinical Practice. *Womens Health Rep (New Rochelle)*. 2022;3: 483–490. doi:10.1089/whr.2021.0139
129. de Arruda GT, de Melo Mantovan SG, Da Roza T, Silva BI da, Tonon da Luz SC, Avila MA. WHODAS measurement properties for women with dysmenorrhea. *Health Qual Life Outcomes*. 2023;21. doi:10.1186/s12955-023-02140-y
130. Teherán A, Pineros LG, Pulido F, Mejía Guatibonza MC. WaLIDD score, a new tool to diagnose dysmenorrhea and predict medical leave in university students. *Int J Womens Health*. 2018;10: 35–45. doi:10.2147/IJWH.S143510
131. Yu S-C, Hsu H-P, Guo J-L, Chen S-F, Huang S-H, Chen Y-C, et al. Exploration of the experiences of working stressors and coping strategies associated with menstrual symptoms among nurses with

- shifting schedules: a Q methodology investigation. *BMC Nurs.* 2021;20: 238. doi:10.1186/s12912-021-00759-0
132. Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, et al. World Endometriosis Research Foundation Endometriosis Phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. *Fertil Steril.* 2014;102: 1223–1232. doi:10.1016/j.fertnstert.2014.07.1244
133. Dimentberg E, Cardailiac C, Richard E, Plante A-S, Maheux-Lacroix S. Translation and Cultural Validation of the WERF EPHEct Endometriosis Patient Questionnaire into Canadian French. *Journal of Obstetrics and Gynaecology Canada.* 2021;43: 817–821. doi:10.1016/j.jogc.2021.03.019
134. Melin A, Tornberg ÅB, Skouby S, Faber J, Ritz C, Sjödin A, et al. The LEAF questionnaire: a screening tool for the identification of female athletes at risk for the female athlete triad. *Br J Sports Med.* 2014;48: 540–545. doi:10.1136/bjsports-2013-093240
135. de Maria UP, Juzwiak CR. Cultural adaptation and validation of the Low Energy Availability in Females Questionnaire (LEAF-Q). *Revista Brasileira de Medicina do Esporte.* 2021;27: 184–188. doi:10.1590/1517-869220212702223889
136. Sutthibut K, Itharat A, Singchungchai P, Wanichsetakul P, Pipatrattanaseree W, Ooraikul B, et al. Development of an Assessment Tool of Menstrual-Cycle-Related Signs and Symptoms Based on Thai Traditional Medicine Principles for Evaluation of Women’s Health. Shang H, editor. *Evidence-Based Complementary and Alternative Medicine.* 2021;2021: 1–16. doi:10.1155/2021/9977773
137. Chesney MA, Tasto DL. The development of the menstrual symptom questionnaire. *Behaviour research and therapy.* 1975;13: 237–44. doi:10.1016/0005-7967(75)90028-5
138. Nelson RO, Sigmon S, Amodei N, Jarrett RB. The menstrual symptom questionnaire: The validity of the distinction between spasmodic and congestive dysmenorrhea. *Behaviour Research and Therapy.* 1984;22: 611–614. doi:10.1016/0005-7967(84)90123-2
139. Negriff S, Dorn LD, Hillman JB, Huang B. The measurement of menstrual symptoms: factor structure of the menstrual symptom questionnaire in adolescent girls. *J Health Psychol.* 2009;14: 899–908. doi:10.1177/1359105309340995
140. Im E-O. The Midlife Women’s Symptom Index (MSI). *Health Care Women Int.* 2006;27: 268–287. doi:10.1080/07399330500506600
141. Mathias SD, Colwell HH, LoCoco JM, Karvois DL, Pritchard ML, Friedman AJ. ORTHO birth control satisfaction assessment tool: assessing sensitivity to change and predictors of satisfaction. *Contraception.* 2006;74: 303–308. doi:10.1016/j.contraception.2006.03.033
142. Colwell HH, Mathias SD, Cimms TA, Rothman M, Friedman AJ, Patrick DL. The ORTHO BC-SAT – a satisfaction questionnaire for women using hormonal contraceptives. *Quality of Life Research.* 2006;15: 1621–1631. doi:10.1007/s11136-006-0026-8

143. Mahalingaiah S, Cosenza C, Cheng JJ, Rodriguez E, Aschengrau A. Cognitive testing of a survey instrument for self-assessed menstrual cycle characteristics and androgen excess. *Fertil Res Pract.* 2020;6: 19. doi:10.1186/s40738-020-00088-x
144. Saei Ghare Naz M, Ozgoli G, Ahmadi F, Alavi Majd H, Aflatounian A, Ramezani Tehrani F. Adolescents' polycystic ovary syndrome health-related quality of life questionnaire (APQ-20): development and psychometric properties. *Eur J Pediatr.* 2023;182. doi:10.1007/s00431-023-04875-8
145. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). *J Clin Endocrinol Metab.* 1998;83: 1976–87. doi:10.1210/jcem.83.6.4990
146. Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, et al. The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. *Hum Reprod.* 2004;19: 371–7. doi:10.1093/humrep/deh048
147. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. *J Clin Epidemiol.* 2004;57: 1279–1287. doi:10.1016/j.jclinepi.2003.10.018
148. Jedel E, Kowalski J, Stener-Victorin E. Assessment of health-related quality of life: Swedish version of polycystic ovary syndrome questionnaire. *Acta Obstet Gynecol Scand.* 2008;87: 1329–35. doi:10.1080/00016340802444762
149. Bazarganipour F, Ziaei S, Montazeri A, Faghihzadeh S, Frozanfard F. Psychometric properties of the Iranian version of modified polycystic ovary syndrome health-related quality-of-life questionnaire. *Human Reproduction.* 2012;27: 2729–2736. doi:10.1093/humrep/des199
150. Bazarganipour F, Ziaei S, Montazeri A, Foroozafard F, Faghihzadeh S. Iranian version of modified polycystic ovary syndrome health-related quality of Life questionnaire: Discriminant and convergent validity. *Iran J Reprod Med.* 2013;11: 753–60. Available: <http://www.ncbi.nlm.nih.gov/pubmed/24639816>
151. Chung J, Kwan A, Kwok J, Chan S. Health-related quality-of-life questionnaire for women with polycystic ovary syndrome: a Chinese translation and validation study. *BJOG.* 2016;123: 1638–45. doi:10.1111/1471-0528.14217
152. Nikpour M, Tirgar A, Ghaffari F, Ebadi A, Sharif Nia H, Nasiri-Amiri F. Development and psychometric evaluation of the women shift workers' reproductive health questionnaire: a sequential exploratory mixed-method study. *Reprod Health.* 2020;17: 147. doi:10.1186/s12978-020-00994-9
153. Morse JM, Kieren D, Bottorff J. The adolescent menstrual attitude questionnaire, part I: Scale construction. *Health Care Women Int.* 1993;14: 39–62. doi:10.1080/07399339309516025
154. Morse JM, Kieren D. The adolescent menstrual attitude questionnaire, part II: Normative scores. *Health Care Women Int.* 1993;14: 63–76. doi:10.1080/07399339309516026

155. Whitham HK, MacLehose RF, Harlow BL, Wellons MF, Schreiner PJ. Assessing the utility of methods for menopausal transition classification in a population-based cohort: The CARDIA Study. *Maturitas*. 2013;75: 289–293. doi:10.1016/j.maturitas.2013.04.015
156. Pedersen SD, Brar S, Faris P, Corenblum B. Polycystic ovary syndrome: validated questionnaire for use in diagnosis. *Can Fam Physician*. 2007;53: 1042–7, 1041. Available: <http://www.ncbi.nlm.nih.gov/pubmed/17872783>
157. Chapron C, Lafay-Pillet M-C, Santulli P, Bourdon M, Maignien C, Gaudet-Chardonnet A, et al. A new validated screening method for endometriosis diagnosis based on patient questionnaires. *EClinicalMedicine*. 2022;44: 101263. doi:10.1016/j.eclinm.2021.101263
158. van Barneveld E, Lim A, van Hanegem N, van Osch F, Vork L, Kruiemel J, et al. Real-time Symptom Assessment in Patients With Endometriosis: Psychometric Evaluation of an Electronic Patient-Reported Outcome Measure, Based on the Experience Sampling Method. *JMIR Form Res*. 2023;7. doi:10.2196/29480
159. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. *Clin Ther*. 2007;29: 950–962. doi:10.1016/j.clinthera.2007.05.005
160. DiBenedetti DB, Soliman AM, Ervin C, Evans E, Coddington CC, Agarwal SK, et al. Development of the Painful Periods Screening Tool for endometriosis. *Postgrad Med*. 2018;130: 694–702. doi:10.1080/00325481.2018.1526623
161. Nasiri-Amiri F, Ramezani Tehrani F, Simbar M, Montazeri A, Mohammadpour RA. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): development and psychometric properties. *Quality of Life Research*. 2016;25: 1791–1801. doi:10.1007/s11136-016-1232-7
162. Stevanovic D, Bozic-Antic I, Stanojlovic O, Vojnovic Milutinovic D, Bjekic-Macut J, Jancic J, et al. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version. *Women Health*. 2019;59: 1015–1025. doi:10.1080/03630242.2019.1587664
163. Hunter EC, Murray SM, Sultana F, Alam MU, Sarker S, Rahman M, et al. Development and validation of the Self-Efficacy in Addressing Menstrual Needs Scale (SAMNS-26) in Bangladeshi schools: A measure of girls' menstrual care confidence. *PLoS One*. 2022;17. doi:10.1371/journal.pone.0275736
164. Rizwana R, Ashraf K. The construction and validation of the Stellenbosch Endometriosis Quality of life measure (SEQOL). *Health Care Women Int*. 2018;39: 1123–1139. doi:10.1080/07399332.2018.1455684
165. Hackethal A, Luck C, von Hobe A-K, Eskef K, Oehmke F, Konrad L. A structured questionnaire improves preoperative assessment of endometriosis patients: a retrospective analysis and prospective trial. *Arch Gynecol Obstet*. 2011;284: 1179–1188. doi:10.1007/s00404-010-1819-0

166. Alexander MS, Biering-Sørensen F, Elliott S, Kreuter M, Sønksen J. International Spinal Cord Injury Female Sexual and Reproductive Function Basic Data Set. *Spinal Cord*. 2011;49: 787–790. doi:10.1038/sc.2011.7
167. Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Agarwal SK, Coddington C, et al. Psychometric assessment of the health-related productivity questionnaire (HRPQ) among women with endometriosis. *Expert Rev Pharmacoecon Outcomes Res*. 2020;20: 531–539. doi:10.1080/14737167.2019.1662301
168. Ruta DA, Garratt AM, Russell IT. Patient centred assessment of quality of life for patients with four common conditions. *Qual Saf Health Care*. 1999;8: 22–29. doi:10.1136/qshc.8.1.22
169. Schneider S, Broderick JE, Junghaenel DU, Schwartz JE, Stone AA. Temporal trends in symptom experience predict the accuracy of recall PROs. *J Psychosom Res*. 2013;75: 160–166. doi:10.1016/j.jpsychores.2013.06.006
170. Pokrzywinski R, Soliman AM, Surrey E, Snabes MC, Coyne KS. Psychometric assessment of the PROMIS Fatigue Short Form 6a in women with moderate-to-severe endometriosis-associated pain. *J Patient Rep Outcomes*. 2020;4: 86. doi:10.1186/s41687-020-00257-y
171. Ferreira-Valente A, Garcia IQ, Rosa AM, Pereira A, Pais-Ribeiro JL, Jensen MP. The Portuguese 35-item Survey of Pain Attitudes applied to Portuguese women with Endometriosis. *Scand J Pain*. 2019;19: 553–563. doi:10.1515/sjpain-2019-0004
172. Hunter M. The women’s health questionnaire: A measure of mid-aged women’s perceptions of their emotional and physical health. *Psychol Health*. 1992;7: 45–54. doi:10.1080/08870449208404294
173. Hunter M. The Women’s Health Questionnaire (WHQ): The development, standardization and application of a measure of mid-aged women’s emotional and physical health. *Quality of Life Research*. 2000;9: 733–738. doi:10.1023/A:1008973822876
174. Colantonio A, Harris JE, Tarek N. Reliability of a Health Questionnaire Among Women With Brain Injury. *Journal of Neuroscience Nursing*. 2011;43: 141–148. doi:10.1097/JNN.0b013e3182135b13

S4 Table. Characteristics of sub-scales, items, and general instruments.

Full Name of instrument	Available Languages	Available Electronically?*	BLEEDING				BLOOD			UTERINE PAIN	PERCEPTIONS	Subscale Topic or Wording of Questions	Ref
			Duration	Volume	Frequency	Regularity	Color	Consistency	Smell				
<b>Instruments with subscales on menstrual changes (n=8)</b>													
Low Energy Availability in Females Questionnaire	Danish, English, Portuguese, Swedish	Yes	X	X	X	X						Menstrual function and use of contraceptives	[134,135]
Menstrual Cycle-Related Signs and Symptoms Questionnaire	Thai	No		X				X	X	X	X	Menstrual cycle-related signs and symptoms (section 1)	[136]
Menstrual Symptom Questionnaire	English	No								X		Spasmodic dysmenorrhea, also called menstrual discomfort or factor 1: abdominal pain in later versions of the too	[137–139]
Midlife Women's Symptom Index	English	No		X	X	X						Self-reported menopausal status (includes last menstrual cycle, menstrual regularity, and menstrual flow)	[140]
ORTHO Birth Control Satisfaction Assessment Tool	English	No	X	X	X					X	X	Menstrual impact and lifestyle impact	[141,142]
Ovulation and Menstruation Health Survey	English	Yes	X	X		X						Menstrual cycle questions	[143]
Polycystic Ovary Syndrome Quality of Life Scale	Chinese, English, Persian, Swedish	No				X				X		Menstrual problems (menstruation or menstrual)	[144–151]
Women Shift Workers Reproductive Health Questionnaire	Persian	No				X				X		Menstruation	[152]
<b>Instruments with items or questions on menstrual changes (n=13)</b>													
Adolescent Menstrual Attitude Questionnaire	English	No				X				X	X	[strongly disagree; disagree; don't care, are not sure, or do not know; agree with the statement; strongly]: "I worry a lot about my periods starting unexpectedly."; "I do not feel any different than usual when I menstruate."; "I feel okay when I get my period."; "When I have my period, I feel good."; "When I get my period, I feel sick."; "Cramps during my period are very painful."; "I feel ugly and gross when I have my period."; "When I am menstruating I feel the same."	[153,154]
CARDIA Women's Reproductive Health Questionnaire	English	Yes				X						"During the past 12 months, have your menstrual cycles been regular at least half the time (excluding times when you were on birth control pills, pregnant, or nursing)? [no, yes, not sure]?"	[155]
Clinical Tool for Diagnosis of PCOS	English	No			X							"Please answer this question NOT INCLUDING any time spent pregnant, receiving birth control pills or injections, after menopause, or after having both ovaries or the uterus surgically removed: Between the ages of 16 and 40, about how long was your average menstrual cycle (time from first day of one period to the first day of the next period)? Select ONE only: [<25 d, 25-34 d, 35-60 d, more than 60 d, totally variable]"	[156]
Clinically Validated Scores for Endometriosis Diagnosis**	French	No								X		Visual analogue scale (range: 0-10): dysmenorrhea ≥6	[157]
Experience Sampling Method	Dutch	Yes								X		"I suffer from abdominal pain."; "I feel pain when I am standing/walking."	[158]
Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ)	Multi-Site Study	No	X	X						X	X	"Thinking about your last period.... How bothered were you by heavier bleeding before having ITP?"; "How bothered were you by bleeding for more days than before having ITP?"; "How bothered were you by more pain before ITP? " [5-point Likert scale from "extremely" to "not at all"]	[159]
Painful Periods Screening Tool	English	No								X	X	"Do you often experience pelvic/abdominal or lower back pain before or during your periods that limits your activities or requires medication?"; Do you sometimes avoid sexual intercourse to avoid pain? [Yes, No, Not applicable, I am not sexually active]"	[160]
Polycystic Ovary Syndrome Questionnaire-50	Persian, Serbian	No									X	"In the past 4 weeks have you ever...Felt concerned about menstruation at long intervals?" [Y/N]	[161,162]
Self-Efficacy in Addressing Menstrual Needs Scale	Bengali	Yes	X							X	X	"How confident are you that you can count/keep track of your period days?"; "How confident are you that you can usually reduce your abdominal pain by a small amount?"; "How confident are you that you can usually reduce most of your abdominal pain?"; "How confident are you that you can usually reduce your abdominal pain completely?"	[163]

Full Name of instrument	Available Languages	Available Electronically?*	BLEEDING				BLOOD			UTERINE PAIN	PERCEPTIONS	Subscale Topic or Wording of Questions	Ref
			Duration	Volume	Frequency	Regularity	Color	Consistency	Smell				
Stellenbosch Endometriosis Quality of Life Measure	English	No						X			X	"I was concerned about the clots in my period."; "I was worried that my period was not normal."; "I felt that my period drained me." [not applicable, not at all, a little bit, somewhat, quite a bit, very much]	[164]
Structured Endometriosis Questionnaire	English, German	Yes		X		X					X	"Do you have a regular menstrual cycle? [Y/N]"; "How long is your average period?"; "How long is your average bleeding?"; "When was the first day of your last period?"; "How do you estimate the intensity of the last menstrual bleeding?"; "Do you have pain in connection with you menstrual bleeding? [Y/N], If yes, when do you feel pain [previously, meanwhile, afterwards] How strong do you feel the pain on a scale from 0 to 10?"	[165]
The International Spinal Cord Injury Female Sexual and Reproductive Function	English	No	X	X	X							"How would you rate your current menstruation pattern? [Normal, Reduced/alterd, Absent, Unknown, Not applicable]"	[166]
Uterine Fibroid Daily Bleeding Diary	Multi-Site Study	No		X								"Rate the severity of any vaginal bleeding in the past 24 hours. [No vaginal bleeding, Spotting, Mild, Moderate, Severe, Very severe]"	[106]
<b>General instruments validate in menstruating populations (n=5)</b>													
Health Related Productivity Questionnaire	Multi-Site Study	Yes									X	NA (General questions applied to menstruating population but no questions specific to menstruation)	[167]
Patient-Generated Index of Quality of Life	English	No									X	"We would like you to think of the most important areas of your life that are affected by your Menorrhagia. Please write up to FIVE areas in the boxes below."	[168]
Patient-Reported Outcomes Measurement Information System	English	Yes	X							X	X	NA (General questions applied to menstruating population but no questions specific to menstruation)	[169,170]
Survey of Pain Attitudes	Portuguese	Yes								X	X	NA (General questions applied to menstruating population but no questions specific to menstruation)	[171]
Women's Health Questionnaire	English	No		X						X		"Please indicate how you are feeling now, or how you have been feeling THE LAST FEW DAYS, by putting a tick in the correct box in the answer to each of the following items [Yes definitely, yes sometimes, no not much, no not at all]: 'I have heavy periods.'; 'My breasts feel tender or uncomfortable.'; 'I have abdominal cramps or discomfort.'"	[172–174]

\*According to publications, "Yes" indicates either fully or partly electronic

\*\*All tools or subscales were designed to be completed by patients or participants, except for the Clinically Validated Scores for Endometriosis Diagnosis

## References

1. Ruta DA, Garratt AM, Chadha YC, Flett GM, Hall MH, Russell IT. Assessment of patients with menorrhagia: How valid is a structured clinical history as a measure of health status? *Quality of Life Research*. 1995;4: 33–40. doi:10.1007/BF00434381
2. Abu-Rafea BF, Vilos GA, Al Jasser RS, Al Anazy RM, Javaid K, Al-Mandeel HM. Linguistic and clinical validation of the Arabic-translated Aberdeen Menorrhagia Severity Scale as an indicator of quality of life for women with abnormal uterine bleeding. *Saudi Med J*. 2012;33: 869–74. Available: <http://www.ncbi.nlm.nih.gov/pubmed/22886120>
3. Ching-Hsing H, Meei-Ling G, Hsin-Chun M, Chung-Yi L. The development and psychometric testing of a self-care scale for dysmenorrhic adolescents. *The journal of nursing research*. 2004;12: 119–30. doi:10.1097/01.jnr.0000387495.01557.aa
4. Wong CL, Ip WY, Choi KC, Shiu TY. Translation and validation of the Chinese-Cantonese version of the Adolescent Dysmenorrhic Self-Care Scale in Hong Kong adolescent girls. *J Clin Nurs*. 2013;22: 1510–1520. doi:10.1111/jocn.12019
5. van Eijkeren MA, Scholten PC, Christiaens GC, Alsbach GP, Haspels AA. The alkaline hematin method for measuring menstrual blood loss--a modification and its clinical use in menorrhagia. *Eur J Obstet Gynecol Reprod Biol*. 1986;22: 345–51. doi:10.1016/0028-2243(86)90124-3
6. Small CM, Manatunga AK, Marcus M. Validity of Self-Reported Menstrual Cycle Length. *Ann Epidemiol*. 2007;17: 163–170. doi:10.1016/j.annepidem.2006.05.005
7. Hudgens S, Gauthier M, Hunsche E, Kang J, Li Y, Scippa K, et al. Development of the Bleeding and Pelvic Discomfort Scale for Use in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids. *Value in Health*. 2022;25. doi:10.1016/j.jval.2022.06.005
8. Paramsothy P, Harlow SD, Elliott MR, Lisabeth LD, Crawford SL, Randolph JF. Classifying menopause stage by menstrual calendars and annual interviews: need for improved questionnaires. *Menopause*. 2013;20: 727–35. doi:10.1097/GME.0b013e3182825ff2
9. Johannes CB, Crawford SL, Woods J, Goldstein RB, Tran D, Mehrotra S, et al. An Electronic Menstrual Cycle Calendar: Comparison of Data Quality With a Paper Version. *Menopause*. 2000;7: 200–208. doi:10.1097/00042192-200007030-00011
10. Nguyen AM, Humphrey L, Kitchen H, Rehman T, Norquist JM. A qualitative study to develop a patient-reported outcome for dysmenorrhea. *Quality of Life Research*. 2015;24: 181–191. doi:10.1007/s11136-014-0755-z
11. Nguyen AM, Arbuckle R, Korver T, Chen F, Taylor B, Turnbull A, et al. Psychometric validation of the dysmenorrhea daily diary (DysDD): a patient-reported outcome for dysmenorrhea. *Quality of Life Research*. 2017;26: 2041–2055. doi:10.1007/s11136-017-1562-0
12. Chen CX, Murphy T, Ofner S, Yahng L, Krombach P, LaPradd M, et al. Development and Testing of the Dysmenorrhea Symptom Interference (DSI) Scale. *West J Nurs Res*. 2021;43: 364–373. doi:10.1177/0193945920942252



13. Gray TG, Moores KL, James E, Connor ME, Jones GL, Radley SC. Development and initial validation of an electronic personal assessment questionnaire for menstrual, pelvic pain and gynaecological hormonal disorders (ePAQ-MPH). *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2019;238: 148–156. doi:10.1016/j.ejogrb.2019.05.024
14. Guan Y, Nguyen AM, Wratten S, Randhawa S, Weaver J, Arbelaez F, et al. The endometriosis daily diary: qualitative research to explore the patient experience of endometriosis and inform the development of a patient-reported outcome (PRO) for endometriosis-related pain. *J Patient Rep Outcomes*. 2022;6: 5. doi:10.1186/s41687-021-00409-8
15. Wyrwich KW, O'Brien CF, Soliman AM, Chwalisz K. Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain. *Reproductive Sciences*. 2018;25: 1567–1576. doi:10.1177/1933719118789509
16. Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C. Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. *Obstetrics and gynecology*. 2001;98: 258–64. doi:10.1016/s0029-7844(01)01433-8
17. Mengarda CV, Passos EP, Picon P, Costa AF, Picon PD. Validação de versão para o português de questionário sobre qualidade de vida para mulher com endometriose (Endometriosis Health Profile Questionnaire - EHP-30). *Revista Brasileira de Ginecologia e Obstetrícia*. 2008;30: 384–392. doi:10.1590/S0100-72032008000800003
18. Grundström H, Rauden A, Olovsson M. Cross-cultural adaptation of the Swedish version of Endometriosis Health Profile-30. *J Obstet Gynaecol (Lahore)*. 2020;40: 969–973. doi:10.1080/01443615.2019.1676215
19. Grundström H, Rauden A, Wikman P, Olovsson M. Psychometric evaluation of the Swedish version of the 30-item endometriosis health profile (EHP-30). *BMC Womens Health*. 2020;20: 204. doi:10.1186/s12905-020-01067-6
20. Jones G, Jenkinson C, Kennedy S. Evaluating the responsiveness of the endometriosis health profile questionnaire: The EHP-30. *Quality of Life Research*. 2004;13: 705–713. doi:10.1023/B:QURE.0000021316.79349.af
21. Jenkinson C, Kennedy S, Jones G. Evaluation of the American version of the 30-item Endometriosis Health Profile (EHP-30). *Quality of Life Research*. 2008;17: 1147–1152. doi:10.1007/s11136-008-9403-9
22. Hansen KE, Lambek R, Røssaak K, Egekvist AG, Marschall H, Forman A, et al. Health-related quality of life in women with endometriosis: psychometric validation of the Endometriosis Health Profile 30 questionnaire using confirmatory factor analysis. *Hum Reprod Open*. 2022;2022. doi:10.1093/hropen/hoab042
23. Khong S-Y, Lam A, Luscombe G. Is the 30-item Endometriosis Health Profile (EHP-30) suitable as a self-report health status instrument for clinical trials? *Fertil Steril*. 2010;94: 1928–1932. doi:10.1016/j.fertnstert.2010.01.047

24. Verket NJ, Andersen MH, Sandvik L, Tanbo TG, Qvigstad E. Lack of cross-cultural validity of the Endometriosis Health Profile-30. *J Endometr Pelvic Pain Disord.* 2018;10: 107–115. doi:10.1177/2284026518780638
25. Jones G, Jenkinson C, Taylor N, Mills A, Kennedy S. Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire. *Human Reproduction.* 2006;21: 2686–2693. doi:10.1093/humrep/del231
26. van de Burgt TJM, Hendriks JCM, Kluivers KB. Quality of life in endometriosis: evaluation of the Dutch-version Endometriosis Health Profile–30 (EHP-30). *Fertil Steril.* 2011;95: 1863–1865. doi:10.1016/j.fertnstert.2010.11.009
27. van de Burgt TJM, Kluivers KB, Hendriks JCM. Responsiveness of the Dutch Endometriosis Health Profile-30 (EHP-30) questionnaire. *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 2013;168: 92–94. doi:10.1016/j.ejogrb.2012.12.037
28. Wickström KW, Spira J, Edelstam G. Responsiveness of the Endometriosis Health Profile-30 questionnaire in a Swedish sample: an observational study. *Clin Exp Obstet Gynecol.* 2017;44: 413–418. doi:10.12891/ceog3599.2017
29. Nojomi M, Bijari B, Akhbari R, Kashanian M. The Assessment of Reliability and Validity of Persian Version of the Endometriosis Health Profile (EHP-30). *Iran J Med Sci.* 2011;36: 84–9. Available: <http://www.ncbi.nlm.nih.gov/pubmed/23358588>
30. Mansor M, Chong MC, Chui PL, Hamdan M, Basha MAMK. The psychometric properties test of the Malay version of the endometriosis health profile-30. *Saudi Med J.* 2023;44. doi:10.15537/smj.2023.44.9.20230228
31. Maiorana A, Scafidi Fonti GM, Audino P, Rosini R, Alio L, Oliveri AM, et al. The role of EHP-30 as specific instrument to assess the quality of life of Italian women with endometriosis. *Minerva Ginecol.* 2012;64: 231–8. Available: <http://www.ncbi.nlm.nih.gov/pubmed/22635018>
32. Marí-Alexandre J, García-Oms J, Agababyan C, Belda-Montesinos R, Royo-Bolea S, Varo-Gómez B, et al. Toward an improved assessment of quality of life in endometriosis: evaluation of the Spanish version of the Endometriosis Health Profile 30. *Journal of Psychosomatic Obstetrics and Gynecology.* 2022;43. doi:10.1080/0167482X.2020.1795827
33. Nogueira-Silva C, Costa P, Martins C, Barata S, Alho C, Calhaz-Jorge C, et al. Validação da Versão Portuguesa do Questionário EHP-30 (The Endometriosis Health Profile-30). *Acta Med Port.* 2015;28: 347–356. doi:10.20344/amp.5778
34. Chauvet P, Auclair C, Mourgues C, Canis M, Gerbaud L, Bourdel N. Psychometric properties of the French version of the Endometriosis Health Profile-30, a health-related quality of life instrument. *J Gynecol Obstet Hum Reprod.* 2017;46: 235–242. doi:10.1016/j.jogoh.2017.02.004
35. Jia S-Z, Leng J-H, Sun P-R, Lang J-H. Translation and psychometric evaluation of the simplified Chinese-version Endometriosis Health Profile-30. *Human Reproduction.* 2013;28: 691–697. doi:10.1093/humrep/des426

36. Jones G, Jenkinson C, Kennedy S. Evaluating the responsiveness of the Endometriosis Health Profile Questionnaire: the EHP-30. *Qual Life Res.* 2004;13: 705–713. doi:10.1023/B:QURE.0000021316.79349.af
37. Fauconnier A, Huchon C, Chaillou L, Aubry G, Renouvel F, Panel P. Development of a French version of the Endometriosis Health Profile 5 (EHP-5): cross-cultural adaptation and psychometric evaluation. *Quality of Life Research.* 2017;26: 213–220. doi:10.1007/s11136-016-1346-y
38. Aubry G, Panel P, Thiollier G, Huchon C, Fauconnier A. Measuring health-related quality of life in women with endometriosis: comparing the clinimetric properties of the Endometriosis Health Profile-5 (EHP-5) and the EuroQol-5D (EQ-5D). *Human Reproduction.* 2017;32: 1258–1269. doi:10.1093/humrep/dex057
39. Mikuš M, Matak L, Vujić G, Škegro B, Škegro I, Augustin G, et al. The short form endometriosis health profile questionnaire (EHP-5): psychometric validity assessment of a Croatian version. *Arch Gynecol Obstet.* 2023;307: 87–92. doi:10.1007/s00404-022-06691-1
40. Selcuk S, Sahin S, Demirci O, Aksoy B, Eroglu M, Ay P, et al. Translation and validation of the Endometriosis Health Profile (EHP-5) in patients with laparoscopically diagnosed endometriosis. *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 2015;185: 41–44. doi:10.1016/j.ejogrb.2014.11.039
41. Moradi M, Parker M, Sneddon A, Lopez V, Ellwood D. The Endometriosis Impact Questionnaire (EIQ): a tool to measure the long-term impact of endometriosis on different aspects of women’s lives. *BMC Womens Health.* 2019;19: 64. doi:10.1186/s12905-019-0762-x
42. Gater A, Taylor F, Seitz C, Gerlinger C, Wichmann K, Haberland C. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). *J Patient Rep Outcomes.* 2020;4: 13. doi:10.1186/s41687-020-0177-3
43. Deal LS, DiBenedetti D, Williams VS, Fehnel SE. The development and validation of the daily electronic Endometriosis Pain and Bleeding Diary. *Health Qual Life Outcomes.* 2010;8: 64. doi:10.1186/1477-7525-8-64
44. van Nooten FE, Cline J, Elash CA, Paty J, Reaney M. Development and content validation of a patient-reported endometriosis pain daily diary. *Health Qual Life Outcomes.* 2018;16: 3. doi:10.1186/s12955-017-0819-1
45. Namazi M, Zareiyan A, Jafarabadi M, Behboodi Moghadam Z. Endometriosis reproductive health questionnaire (ERHQ): A self-administered questionnaire to measure the reproductive health in women with endometriosis. *J Gynecol Obstet Hum Reprod.* 2021;50: 101860. doi:10.1016/j.jogoh.2020.101860
46. Cho H-H, Yoon Y-S. Development of an endometriosis self-assessment tool for patient. *Obstet Gynecol Sci.* 2022;65: 256–265. doi:10.5468/ogs.21252

47. Deal LS, Williams VSL, DiBenedetti DB, Fehnel SE. Development and psychometric evaluation of the Endometriosis Treatment Satisfaction Questionnaire. *Quality of Life Research*. 2010;19: 899–905. doi:10.1007/s11136-010-9640-6
48. Fauconnier A, Staraci S, Darai E, Descamps P, Nisolle M, Panel P, et al. A self-administered questionnaire to measure the painful symptoms of endometriosis: Results of a modified DELPHI survey of patients and physicians. *J Gynecol Obstet Hum Reprod*. 2018;47: 69–79. doi:10.1016/j.jogoh.2017.11.003
49. Puchar A, Panel P, Oppenheimer A, Du Cheyron J, Fritel X, Fauconnier A. The ENDOPAIN 4D Questionnaire: A New Validated Tool for Assessing Pain in Endometriosis. *J Clin Med*. 2021;10: 3216. doi:10.3390/jcm10153216
50. Ahmadpour P, Jahangiry L, Bani S, Iravani M, Mirghafourvand M. Validation of the Iranian version of the ENDOPAIN-4D questionnaire for measurement of painful symptoms of endometriosis. *J Obstet Gynaecol (Lahore)*. 2022;42. doi:10.1080/01443615.2022.2049726
51. As-Sanie S, Laufer MR, Missmer SA, Murji A, Vincent K, Eichner S, et al. Development of a visual, patient-reported tool for assessing the multi-dimensional burden of endometriosis. *Curr Med Res Opin*. 2021;37: 1443–1449. doi:10.1080/03007995.2021.1929896
52. Deal LS, Williams VSL, Fehnel SE. Development of an Electronic Daily Uterine Fibroid Symptom Diary. *The Patient: Patient-Centered Outcomes Research*. 2011;4: 31–44. doi:10.2165/11537290-000000000-00000
53. Li L, Huangfu L, Chai H, He W, Song H, Zou X, et al. Development of a functional and emotional measure of dysmenorrhea (FEMD) in Chinese university women. *Health Care Women Int*. 2012;33: 97–108. doi:10.1080/07399332.2011.603863
54. Yamada K, Adachi T, Kubota Y, Takeda T, Iseki M. Developing a Japanese version of the Injustice Experience Questionnaire-chronic and the contribution of perceived injustice to severity of menstrual pain: a web-based cross-sectional study. *Biopsychosoc Med*. 2019;13: 17. doi:10.1186/s13030-019-0158-z
55. Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. *Women's Health Issues*. 2004;14: 242–247. doi:10.1016/j.whi.2004.07.005
56. Olliges E, Bobinger A, Weber A, Hoffmann V, Schmitz T, Popovici RM, et al. The Physical, Psychological, and Social Day-to-Day Experience of Women Living With Endometriosis Compared to Healthy Age-Matched Controls—A Mixed-Methods Study. *Front Glob Womens Health*. 2021;2: 767114. doi:10.3389/fgwh.2021.767114
57. Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. *Curr Med Res Opin*. 2010;26: 2745–55. doi:10.1185/03007995.2010.532200
58. Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. *BJOG*. 1998;105: 1155–1159. doi:10.1111/j.1471-0528.1998.tb09968.x

59. Habiba M, Julian S, Taub N, Clark M, Rashid A, Baker R, et al. Limited role of multi-attribute utility scale and SF-36 in predicting management outcome of heavy menstrual bleeding. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2010;148: 81–85. doi:10.1016/j.ejogrb.2009.09.021
60. Pattison H, Daniels J, Kai J, Gupta J. The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis. *BJOG*. 2011;118: 1528–1531. doi:10.1111/j.1471-0528.2011.03057.x
61. Brooks-Gunn J, Ruble DN. The menstrual attitude questionnaire. *Psychosom Med*. 1980;42: 503–12. doi:10.1097/00006842-198009000-00005
62. Bramwell RS, Biswas EL, Anderson C. Using the Menstrual Attitude Questionnaire with a British and an Indian sample. *J Reprod Infant Psychol*. 2002;20: 159–170. doi:10.1080/026468302760270818
63. Firat MZ, Kulakaç Ö, Öncel S, Akcan A. Menstrual Attitude Questionnaire: confirmatory and exploratory factor analysis with Turkish samples. *J Adv Nurs*. 2009;65: 652–662. doi:10.1111/j.1365-2648.2008.04919.x
64. Bargiota S, Bonotis K, Garyfallos G, Messinis I, Angelopoulos N. The Psychometric Properties of Menstrual Attitudes Questionnaire: A validity Study in Greek Women. *Int J Innov Res Sci Eng Technol*. 2016;5: 1754–1765. doi:10.15680/IJIRSET.2016.0502109
65. Kawata R, Endo M, Rai SK, Ohashi K. Development of a scale to evaluate negative menstrual attitudes among Nepalese women. *Reprod Health*. 2022;19: 120. doi:10.1186/s12978-022-01426-6
66. Rezende GP, Brito LGO, Gomes DAY, Souza LM de, Polo S, Benetti-Pinto CL. Assessing a cut-off point for the diagnosis of abnormal uterine bleeding using the Menstrual Bleeding Questionnaire (MBQ): a validation and cultural translation study with Brazilian women. *Sao Paulo Med J*. 2023;142: e2022539. doi:10.1590/1516-3180.2022.0539.R2.100423
67. Matteson KA, Scott DM, Raker CA, Clark MA. The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. *BJOG*. 2015;122: 681–9. doi:10.1111/1471-0528.13273
68. Pike M, Chopek A, NL Y, Usuba K, MJ B, McLaughlin R, et al. Quality of life in adolescents with heavy menstrual bleeding: Validation of the Adolescent Menstrual Bleeding Questionnaire (aMBQ). *Res Pract Thromb Haemost*. 2021;5: e12615. doi:10.1002/rth2.12615
69. Rodpetch T, Manonai J, Angchaisuksiri P, Boonyawat K. A quality-of-life questionnaire for heavy menstrual bleeding in Thai women receiving oral antithrombotics: Assessment of the translated Menstrual Bleeding Questionnaire. *Res Pract Thromb Haemost*. 2021;5: e12617. doi:10.1002/rth2.12617
70. Toxqui L, Pérez-Granados AM, Blanco-Rojo R, Wright I, Vaquero MP. A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and

- gynecological parameters in young women. *BMC Womens Health*. 2014;14: 71.  
doi:10.1186/1472-6874-14-71
71. Chimbira TH, Anderson AB, Turnbull A c. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. *Br J Obstet Gynaecol*. 1980;87: 603–9.  
doi:10.1111/j.1471-0528.1980.tb05013.x
  72. Gleeson N, Devitt M, Buggy F, Bonnar J. Menstrual Blood Loss Measurement with Gynaeseal. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 1993;33: 79–80.  
doi:10.1111/j.1479-828X.1993.tb02061.x
  73. Gannon MJ, Day P, Hammadih N, Johnson N. A new method for measuring menstrual blood loss and its use in screening women before endometrial ablation. *BJOG*. 1996;103: 1029–1033.  
doi:10.1111/j.1471-0528.1996.tb09556.x
  74. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. *Obstetrics and gynecology*. 2001;98: 806–14.  
doi:10.1016/s0029-7844(01)01581-2
  75. Gudmundsdottir BR, Hjaltalin EF, Bragadottir G, Hauksson A, Geirsson RT, Onundarson PT. Quantification of menstrual flow by weighing protective pads in women with normal, decreased or increased menstruation. *Acta Obstet Gynecol Scand*. 2009;88: 275–9.  
doi:10.1080/00016340802673162
  76. Moos RH. The development of a menstrual distress questionnaire. *Psychosom Med*. 1968;30: 853–67. doi:10.1097/00006842-196811000-00006
  77. Lee AM, So-Kum Tang C, Chong C. A culturally sensitive study of premenstrual and menstrual symptoms among Chinese women. *Journal of Psychosomatic Obstetrics & Gynecology*. 2009;30: 105–114. doi:10.1080/01674820902789241
  78. Vannuccini S, Rossi E, Cassioli E, Cirone D, Castellini G, Ricca V, et al. Menstrual Distress Questionnaire (MEDI-Q): a new tool to assess menstruation-related distress. *Reprod Biomed Online*. 2021;43: 1107–1116. doi:10.1016/j.rbmo.2021.08.029
  79. Cassioli E, Rossi E, Melani G, Faldi M, Rellini AH, Wyatt RB, et al. The menstrual distress questionnaire (MEDI-Q): reliability and validity of the English version. *Gynecological Endocrinology*. 2023;39. doi:10.1080/09513590.2023.2227275
  80. Shin H, Park Y-J, Cho I. Development and psychometric validation of the Menstrual Health Instrument (MHI) for adolescents in Korea. *Health Care Women Int*. 2018;39: 1090–1109.  
doi:10.1080/07399332.2017.1423487
  81. Darabi F, Yaseri M, Rohban A, Khalajabadi-Farahani F. Development and Psychometric Properties of Menstrual Health Seeking Behaviors Questionnaire (MHSBQ-42) in Female Adolescents. *J Reprod Infertil*. 2018;19: 229–236. Available: <http://www.ncbi.nlm.nih.gov/pubmed/30746338>

82. Ramaiya A, Sood S. What are the psychometric properties of a menstrual hygiene management scale: a community-based cross-sectional study. *BMC Public Health*. 2020;20: 525. doi:10.1186/s12889-020-08627-3
83. Caruso BA, Portela G, McManus S, Clasen T. Assessing Women's Menstruation Concerns and Experiences in Rural India: Development and Validation of a Menstrual Insecurity Measure. *Int J Environ Res Public Health*. 2020;17: 3468. doi:10.3390/ijerph17103468
84. Aubeeluck A, Maguire M. The Menstrual Joy Questionnaire Items Alone Can Positively Prime Reporting of Menstrual Attitudes and Symptoms. *Psychol Women Q*. 2002;26: 160–162. doi:10.1111/1471-6402.00054
85. Hennegan J, Nansubuga A, Akullo A, Smith C, Schwab KJ. The Menstrual Practices Questionnaire (MPQ): development, elaboration, and implications for future research. *Glob Health Action*. 2020;13: 1829402. doi:10.1080/16549716.2020.1829402
86. Heath AL, Skeaff CM, Gibson RS. Validation of a questionnaire method for estimating extent of menstrual blood loss in young adult women. *J Trace Elem Med Biol*. 1999;12: 231–5. doi:10.1016/S0946-672X(99)80063-7
87. Roberts T-A. Female Trouble: The Menstrual Self-Evaluation Scale and Women's Self-Objectification. *Psychol Women Q*. 2004;28: 22–26. doi:10.1111/j.1471-6402.2004.00119.x
88. Garg S, Marimuthu Y, Bhatnagar N, Singh MmC, Borle A, Basu S, et al. Development and validation of a menstruation-related activity restriction questionnaire among adolescent girls in urban resettlement colonies of Delhi. *Indian Journal of Community Medicine*. 2021;46: 57. doi:10.4103/ijcm.IJCM\_183\_20
89. Trego LL. Development of the Military Women's Attitudes Toward Menstrual Suppression Scale: From Construct Definition to Pilot Testing. *J Nurs Meas*. 2009;17: 45–72. doi:10.1891/1061-3749.17.1.45
90. Farquhar CM, Roberts H, Okonkwo QL, Stewart AW. A pilot survey of the impact of menstrual cycles on adolescent health. *Aust N Z J Obstet Gynaecol*. 2009;49: 531–6. doi:10.1111/j.1479-828X.2009.01062.x
91. de Arruda GT, Driusso P, Rodrigues JC, de Godoy AG, Avila MA. Numerical rating scale for dysmenorrhea-related pain: a clinimetric study. *Gynecological Endocrinology*. 2022;38. doi:10.1080/09513590.2022.2099831
92. Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. *Fertil Steril*. 2021;115: 423–430. doi:10.1016/j.fertnstert.2020.07.013
93. Rodrigues JC, Avila MA, dos Reis FJJ, Carlessi RM, Godoy AG, Arruda GT, et al. 'Painting my pain': the use of pain drawings to assess multisite pain in women with primary dysmenorrhea. *BMC Womens Health*. 2022;22. doi:10.1186/s12905-022-01945-1

94. Parker MA, Kent AL, Sneddon A, Wang J, Shadbolt B. The Menstrual Disorder of Teenagers (MDOT) Study No. 2: Period ImPact and Pain Assessment (PIPPA) Tool Validation in a Large Population-Based Cross-Sectional Study of Australian Teenagers. *J Pediatr Adolesc Gynecol*. 2022;35: 30–38. doi:10.1016/j.jpog.2021.06.003
95. Lancastle D, Kopp Kallner H, Hale G, Wood B, Ashcroft L, Driscoll H. Development of a brief menstrual quality of life measure for women with heavy menstrual bleeding. *BMC Womens Health*. 2023;23. doi:10.1186/s12905-023-02235-0
96. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. *Br J Obstet Gynaecol*. 1990;97: 734–9. doi:10.1111/j.1471-0528.1990.tb16249.x
97. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. *Obstetrics and gynecology*. 1995;85: 977–82. doi:10.1016/0029-7844(95)00062-V
98. Barr F, Brabin L, Agbaje O. A pictorial chart for managing common menstrual disorders in Nigerian adolescents. *Int J Gynaecol Obstet*. 1999;66: 51–3. doi:10.1016/s0020-7292(99)00025-9
99. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. *BJOG*. 2000;107: 320–322. doi:10.1111/j.1471-0528.2000.tb13225.x
100. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PMS. Determination of total menstrual blood loss. *Fertil Steril*. 2001;76: 125–131. doi:10.1016/S0015-0282(01)01847-7
101. Sanchez J, Andrabi S, Bercaw JL, Dietrich JE. Quantifying the PBAC in a Pediatric and Adolescent Gynecology Population. *Pediatr Hematol Oncol*. 2012;29: 479–484. doi:10.3109/08880018.2012.699165
102. Larsen L, Coyne K, Chwalisz K. Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. *Reprod Sci*. 2013;20: 680–7. doi:10.1177/1933719112463252
103. Magnay JL, Nevatte TM, Seitz C, O'Brien S. A new menstrual pictogram for use with feminine products that contain superabsorbent polymers. *Fertil Steril*. 2013;100: 1715-21.e1–4. doi:10.1016/j.fertnstert.2013.08.028
104. Magnay JL, Nevatte TM, O'Brien S, Gerlinger C, Seitz C. Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers. *Fertil Steril*. 2014;101: 515–22. doi:10.1016/j.fertnstert.2013.10.051
105. Hald K, Lieng M. Assessment of Periodic Blood Loss: Interindividual and Intraindividual Variations of Pictorial Blood Loss Assessment Chart Registrations. *J Minim Invasive Gynecol*. 2014;21: 662–668. doi:10.1016/j.jmig.2014.01.015
106. Haberland C, Filonenko A, Seitz C, Börner M, Gerlinger C, Doll H, et al. Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies. *J Patient Rep Outcomes*. 2020;4: 97. doi:10.1186/s41687-020-00263-0



107. Weller A, Weller L. Assessment of menstrual regularity and irregularity using self-reports and objective criteria. *Journal of Psychosomatic Obstetrics & Gynecology*. 1998;19: 111–116. doi:10.3109/01674829809048504
108. Schumacher U, Schumacher J, Mellinger U, Gerlinger C, Wienke A, Endrikat J. Estimation of menstrual blood loss volume based on menstrual diary and laboratory data. *BMC Womens Health*. 2012;12: 24. doi:10.1186/1472-6874-12-24
109. Wegienka G, Baird DD. A comparison of recalled date of last menstrual period with prospectively recorded dates. *J Womens Health (Larchmt)*. 2005;14: 248–52. doi:10.1089/jwh.2005.14.248
110. Jukic AMZ, Weinberg CR, Baird DD, Hornsby PP, Wilcox AJ. Measuring Menstrual Discomfort. *Epidemiology*. 2008;19: 846–850. doi:10.1097/EDE.0b013e318187ac9e
111. Bachand AM, Cragin LA, Reif JS. Reliability of Retrospectively Assessed Categorical Menstrual Cycle Length Data. *Ann Epidemiol*. 2009;19: 501–503. doi:10.1016/j.annepidem.2009.03.015
112. Jukic AMZ, Weinberg CR, Wilcox AJ, McConaughy DR, Hornsby P, Baird DD. Accuracy of Reporting of Menstrual Cycle Length. *Am J Epidemiol*. 2007;167: 25–33. doi:10.1093/aje/kwm265
113. Calaf J, Cancelo MJ, Andeyro M, Jiménez JM, Perelló J, Correa M, et al. Development and Psychometric Validation of a Screening Questionnaire to Detect Excessive Menstrual Blood Loss That Interferes in Quality of Life: The SAMANTA Questionnaire. *J Womens Health (Larchmt)*. 2020;29: 1021–1031. doi:10.1089/jwh.2018.7446
114. Perelló-Capo J, Rius-Tarruella J, Andeyro-García M, Calaf-Alsina J. Sensitivity to Change of the SAMANTA Questionnaire, a Heavy Menstrual Bleeding Diagnostic Tool, after 1 Year of Hormonal Treatment. *J Womens Health*. 2023;32. doi:10.1089/jwh.2022.0155
115. Pérez-Campos E, Dueñas JL, de la Viuda E, Gómez MÁ, Lertxundi R, Sánchez-Borrego R, et al. Development and validation of the SEC-QOL questionnaire in women using contraceptive methods. *Value Health*. 2011;14: 892–9. doi:10.1016/j.jval.2011.08.1729
116. Kantarovich D, Dillane KE, Garrison EF, Oladosu FA, Schroer MS, Roth GE, et al. Development and validation of a real-time method characterizing spontaneous pain in women with dysmenorrhea. *Journal of Obstetrics and Gynaecology Research*. 2021;47: 1472–1480. doi:10.1111/jog.14663
117. Spies JB, Coyne K, Guaou G, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. *Obstetrics and gynecology*. 2002;99: 290–300. doi:10.1016/s0029-7844(01)01702-1
118. Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). *Health Qual Life Outcomes*. 2008;6: 99. doi:10.1186/1477-7525-6-99
119. Silva R, Gomes M, Castro R, Bonduki C, Girão M. Uterine Fibroid Symptom - Quality of Life questionnaire translation and validation into Brazilian Portuguese. *Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics*. 2016;38: 518–523. doi:10.1055/s-0036-1593833

120. Oliveira Brito LG, Malzone-Lott DA, Sandoval Fagundes MF, Magnani PS, Fernandes Arouca MA, Poli-Neto OB, et al. Translation and validation of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire for the Brazilian Portuguese language. *Sao Paulo Medical Journal*. 2017;135: 107–115. doi:10.1590/1516-3180.2016.0223281016
121. Coyne KS, Soliman AM, Margolis MK, Thompson CL, Chwalisz K. Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire. *Curr Med Res Opin*. 2017;33: 193–200. doi:10.1080/03007995.2016.1248382
122. Coyne KS, Harrington A, Currie BM, Chen J, Gillard P, Spies JB. Psychometric validation of the 1-month recall Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL). *J Patient Rep Outcomes*. 2019;3: 57. doi:10.1186/s41687-019-0146-x
123. Yeung S, Kwok JW, Law S, Chung JP, Chan SS. Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire: a Chinese translation and validation study. *Hong Kong Medical Journal*. 2019;25: 453–459. doi:10.12809/hkmj198064
124. Calaf J, Palacios S, Cristóbal I, Cañete ML, Monleón J, Fernández J, et al. Validation of the Spanish version of the Uterine Fibroid Symptom and Quality of Life (UFS-QoL) questionnaire in women with uterine myomatosis. *Med Clin (Barc)*. 2020;154: 207–213. doi:10.1016/j.medcli.2019.05.027
125. Keizer AL, van Kesteren PJM, Terwee C, de Lange ME, Hehenkamp WJK, Kok HS. Uterine Fibroid Symptom and Quality of Life questionnaire (UFS-QOL NL) in the Dutch population: a validation study. *BMJ Open*. 2021;11: e052664. doi:10.1136/bmjopen-2021-052664
126. Gerlinger C, Schumacher U, Wentzack R, Uhl-Hochgräber K, Solomayer EF, Schmitz H, et al. How can we measure endometriosis-associated pelvic pain? *J Endometr*. 2012;4: 109–116. doi:10.5301/JE.2012.9725
127. Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. *Health Qual Life Outcomes*. 2010;8: 138. doi:10.1186/1477-7525-8-138
128. Perelló J, Pujol P, Pérez M, Artés M, Calaf J. Heavy Menstrual Bleeding-Visual Analog Scale, an Easy-to-Use Tool for Excessive Menstrual Blood Loss That Interferes with Quality-of-Life Screening in Clinical Practice. *Womens Health Rep (New Rochelle)*. 2022;3: 483–490. doi:10.1089/whr.2021.0139
129. de Arruda GT, de Melo Mantovan SG, Da Roza T, Silva BI da, Tonon da Luz SC, Avila MA. WHODAS measurement properties for women with dysmenorrhea. *Health Qual Life Outcomes*. 2023;21. doi:10.1186/s12955-023-02140-y
130. Teherán A, Pineros LG, Pulido F, Mejía Guatibonza MC. WaLIDD score, a new tool to diagnose dysmenorrhea and predict medical leave in university students. *Int J Womens Health*. 2018;10: 35–45. doi:10.2147/IJWH.S143510
131. Yu S-C, Hsu H-P, Guo J-L, Chen S-F, Huang S-H, Chen Y-C, et al. Exploration of the experiences of working stressors and coping strategies associated with menstrual symptoms among nurses with

- shifting schedules: a Q methodology investigation. *BMC Nurs.* 2021;20: 238. doi:10.1186/s12912-021-00759-0
132. Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, et al. World Endometriosis Research Foundation Endometriosis Phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. *Fertil Steril.* 2014;102: 1223–1232. doi:10.1016/j.fertnstert.2014.07.1244
  133. Dimentberg E, Cardailiac C, Richard E, Plante A-S, Maheux-Lacroix S. Translation and Cultural Validation of the WERF EPHEct Endometriosis Patient Questionnaire into Canadian French. *Journal of Obstetrics and Gynaecology Canada.* 2021;43: 817–821. doi:10.1016/j.jogc.2021.03.019
  134. Melin A, Tornberg ÅB, Skouby S, Faber J, Ritz C, Sjödin A, et al. The LEAF questionnaire: a screening tool for the identification of female athletes at risk for the female athlete triad. *Br J Sports Med.* 2014;48: 540–545. doi:10.1136/bjsports-2013-093240
  135. de Maria UP, Juzwiak CR. Cultural adaptation and validation of the Low Energy Availability in Females Questionnaire (LEAF-Q). *Revista Brasileira de Medicina do Esporte.* 2021;27: 184–188. doi:10.1590/1517-869220212702223889
  136. Sutthibut K, Itharat A, Singchungchai P, Wanichsetakul P, Pipatrattanaseree W, Ooraikul B, et al. Development of an Assessment Tool of Menstrual-Cycle-Related Signs and Symptoms Based on Thai Traditional Medicine Principles for Evaluation of Women’s Health. Shang H, editor. *Evidence-Based Complementary and Alternative Medicine.* 2021;2021: 1–16. doi:10.1155/2021/9977773
  137. Chesney MA, Tasto DL. The development of the menstrual symptom questionnaire. *Behaviour research and therapy.* 1975;13: 237–44. doi:10.1016/0005-7967(75)90028-5
  138. Nelson RO, Sigmon S, Amodei N, Jarrett RB. The menstrual symptom questionnaire: The validity of the distinction between spasmodic and congestive dysmenorrhea. *Behaviour Research and Therapy.* 1984;22: 611–614. doi:10.1016/0005-7967(84)90123-2
  139. Negriff S, Dorn LD, Hillman JB, Huang B. The measurement of menstrual symptoms: factor structure of the menstrual symptom questionnaire in adolescent girls. *J Health Psychol.* 2009;14: 899–908. doi:10.1177/1359105309340995
  140. Im E-O. The Midlife Women’s Symptom Index (MSI). *Health Care Women Int.* 2006;27: 268–287. doi:10.1080/07399330500506600
  141. Mathias SD, Colwell HH, LoCoco JM, Karvois DL, Pritchard ML, Friedman AJ. ORTHO birth control satisfaction assessment tool: assessing sensitivity to change and predictors of satisfaction. *Contraception.* 2006;74: 303–308. doi:10.1016/j.contraception.2006.03.033
  142. Colwell HH, Mathias SD, Cimms TA, Rothman M, Friedman AJ, Patrick DL. The ORTHO BC-SAT – a satisfaction questionnaire for women using hormonal contraceptives. *Quality of Life Research.* 2006;15: 1621–1631. doi:10.1007/s11136-006-0026-8

143. Mahalingaiah S, Cosenza C, Cheng JJ, Rodriguez E, Aschengrau A. Cognitive testing of a survey instrument for self-assessed menstrual cycle characteristics and androgen excess. *Fertil Res Pract.* 2020;6: 19. doi:10.1186/s40738-020-00088-x
144. Saei Ghare Naz M, Ozgoli G, Ahmadi F, Alavi Majd H, Aflatounian A, Ramezani Tehrani F. Adolescents' polycystic ovary syndrome health-related quality of life questionnaire (APQ-20): development and psychometric properties. *Eur J Pediatr.* 2023;182. doi:10.1007/s00431-023-04875-8
145. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). *J Clin Endocrinol Metab.* 1998;83: 1976–87. doi:10.1210/jcem.83.6.4990
146. Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, et al. The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. *Hum Reprod.* 2004;19: 371–7. doi:10.1093/humrep/deh048
147. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. *J Clin Epidemiol.* 2004;57: 1279–1287. doi:10.1016/j.jclinepi.2003.10.018
148. Jedel E, Kowalski J, Stener-Victorin E. Assessment of health-related quality of life: Swedish version of polycystic ovary syndrome questionnaire. *Acta Obstet Gynecol Scand.* 2008;87: 1329–35. doi:10.1080/00016340802444762
149. Bazarganipour F, Ziaei S, Montazeri A, Faghihzadeh S, Frozanfard F. Psychometric properties of the Iranian version of modified polycystic ovary syndrome health-related quality-of-life questionnaire. *Human Reproduction.* 2012;27: 2729–2736. doi:10.1093/humrep/des199
150. Bazarganipour F, Ziaei S, Montazeri A, Foroozanfard F, Faghihzadeh S. Iranian version of modified polycystic ovary syndrome health-related quality of Life questionnaire: Discriminant and convergent validity. *Iran J Reprod Med.* 2013;11: 753–60. Available: <http://www.ncbi.nlm.nih.gov/pubmed/24639816>
151. Chung J, Kwan A, Kwok J, Chan S. Health-related quality-of-life questionnaire for women with polycystic ovary syndrome: a Chinese translation and validation study. *BJOG.* 2016;123: 1638–45. doi:10.1111/1471-0528.14217
152. Nikpour M, Tirgar A, Ghaffari F, Ebadi A, Sharif Nia H, Nasiri-Amiri F. Development and psychometric evaluation of the women shift workers' reproductive health questionnaire: a sequential exploratory mixed-method study. *Reprod Health.* 2020;17: 147. doi:10.1186/s12978-020-00994-9
153. Morse JM, Kieren D, Bottorff J. The adolescent menstrual attitude questionnaire, part I: Scale construction. *Health Care Women Int.* 1993;14: 39–62. doi:10.1080/07399339309516025
154. Morse JM, Kieren D. The adolescent menstrual attitude questionnaire, part II: Normative scores. *Health Care Women Int.* 1993;14: 63–76. doi:10.1080/07399339309516026

155. Whitham HK, MacLehose RF, Harlow BL, Wellons MF, Schreiner PJ. Assessing the utility of methods for menopausal transition classification in a population-based cohort: The CARDIA Study. *Maturitas*. 2013;75: 289–293. doi:10.1016/j.maturitas.2013.04.015
156. Pedersen SD, Brar S, Faris P, Corenblum B. Polycystic ovary syndrome: validated questionnaire for use in diagnosis. *Can Fam Physician*. 2007;53: 1042–7, 1041. Available: <http://www.ncbi.nlm.nih.gov/pubmed/17872783>
157. Chapron C, Lafay-Pillet M-C, Santulli P, Bourdon M, Maignien C, Gaudet-Chardonnet A, et al. A new validated screening method for endometriosis diagnosis based on patient questionnaires. *EClinicalMedicine*. 2022;44: 101263. doi:10.1016/j.eclinm.2021.101263
158. van Barneveld E, Lim A, van Hanegem N, van Osch F, Vork L, Kruiemel J, et al. Real-time Symptom Assessment in Patients With Endometriosis: Psychometric Evaluation of an Electronic Patient-Reported Outcome Measure, Based on the Experience Sampling Method. *JMIR Form Res*. 2023;7. doi:10.2196/29480
159. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. *Clin Ther*. 2007;29: 950–962. doi:10.1016/j.clinthera.2007.05.005
160. DiBenedetti DB, Soliman AM, Ervin C, Evans E, Coddington CC, Agarwal SK, et al. Development of the Painful Periods Screening Tool for endometriosis. *Postgrad Med*. 2018;130: 694–702. doi:10.1080/00325481.2018.1526623
161. Nasiri-Amiri F, Ramezani Tehrani F, Simbar M, Montazeri A, Mohammadpour RA. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): development and psychometric properties. *Quality of Life Research*. 2016;25: 1791–1801. doi:10.1007/s11136-016-1232-7
162. Stevanovic D, Bozic-Antic I, Stanojlovic O, Vojnovic Milutinovic D, Bjekic-Macut J, Jancic J, et al. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version. *Women Health*. 2019;59: 1015–1025. doi:10.1080/03630242.2019.1587664
163. Hunter EC, Murray SM, Sultana F, Alam MU, Sarker S, Rahman M, et al. Development and validation of the Self-Efficacy in Addressing Menstrual Needs Scale (SAMNS-26) in Bangladeshi schools: A measure of girls' menstrual care confidence. *PLoS One*. 2022;17. doi:10.1371/journal.pone.0275736
164. Rizwana R, Ashraf K. The construction and validation of the Stellenbosch Endometriosis Quality of life measure (SEQOL). *Health Care Women Int*. 2018;39: 1123–1139. doi:10.1080/07399332.2018.1455684
165. Hackethal A, Luck C, von Hobe A-K, Eskef K, Oehmke F, Konrad L. A structured questionnaire improves preoperative assessment of endometriosis patients: a retrospective analysis and prospective trial. *Arch Gynecol Obstet*. 2011;284: 1179–1188. doi:10.1007/s00404-010-1819-0

166. Alexander MS, Biering-Sørensen F, Elliott S, Kreuter M, Sønksen J. International Spinal Cord Injury Female Sexual and Reproductive Function Basic Data Set. *Spinal Cord*. 2011;49: 787–790. doi:10.1038/sc.2011.7
167. Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Agarwal SK, Coddington C, et al. Psychometric assessment of the health-related productivity questionnaire (HRPQ) among women with endometriosis. *Expert Rev Pharmacoecon Outcomes Res*. 2020;20: 531–539. doi:10.1080/14737167.2019.1662301
168. Ruta DA, Garratt AM, Russell IT. Patient centred assessment of quality of life for patients with four common conditions. *Qual Saf Health Care*. 1999;8: 22–29. doi:10.1136/qshc.8.1.22
169. Schneider S, Broderick JE, Junghaenel DU, Schwartz JE, Stone AA. Temporal trends in symptom experience predict the accuracy of recall PROs. *J Psychosom Res*. 2013;75: 160–166. doi:10.1016/j.jpsychores.2013.06.006
170. Pokrzywinski R, Soliman AM, Surrey E, Snabes MC, Coyne KS. Psychometric assessment of the PROMIS Fatigue Short Form 6a in women with moderate-to-severe endometriosis-associated pain. *J Patient Rep Outcomes*. 2020;4: 86. doi:10.1186/s41687-020-00257-y
171. Ferreira-Valente A, Garcia IQ, Rosa AM, Pereira A, Pais-Ribeiro JL, Jensen MP. The Portuguese 35-item Survey of Pain Attitudes applied to Portuguese women with Endometriosis. *Scand J Pain*. 2019;19: 553–563. doi:10.1515/sjpain-2019-0004
172. Hunter M. The women's health questionnaire: A measure of mid-aged women's perceptions of their emotional and physical health. *Psychol Health*. 1992;7: 45–54. doi:10.1080/08870449208404294
173. Hunter M. The Women's Health Questionnaire (WHQ): The development, standardization and application of a measure of mid-aged women's emotional and physical health. *Quality of Life Research*. 2000;9: 733–738. doi:10.1023/A:1008973822876
174. Colantonio A, Harris JE, Tarek N. Reliability of a Health Questionnaire Among Women With Brain Injury. *Journal of Neuroscience Nursing*. 2011;43: 141–148. doi:10.1097/JNN.0b013e3182135b13